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The adaptive immune response to an allograft is initiated when donor-derived foreign 
antigens are recognised by the host immune system. This process relies on efficient 
trafficking of immune cells out of the graft to secondary lymphoid organs which provide 
a suitable niche for interactions between antigen presenting cells and allo-reactive T 
cells. The role of the lymphatic system in the allo-response is poorly understood, and 
there is evidence that lymphatics can have either a negative or a positive impact on graft 
survival, depending on a variety of complex factors.  
 
The contribution of lymphatics to the allo-response has been studied using mouse 
models of skin, heart and kidney transplantation, in conjunction with pharmacological or 
genetic modulation of lymphatic function. Allogeneic kidney graft survival was 
significantly prolonged following treatment of recipients with anti-ICAM-1, an effect which 
correlated with reduced density of donor passenger leukocytes within recipients' draining 
lymph nodes in the immediate post-transplantation period. In addition, skin, heart and 
kidney grafts with lymphatic deletion of ephrin B2 benefitted from prolonged survival 
compared with wild-type grafts. This could not be attributed to reduced trafficking of 
donor cells to the draining lymph nodes and was likely a result of a local protective effect 
of ephrin B2 deficiency in the graft. The draining lymph node lymphatic response to heart 
transplantation was assessed; however, no significant changes were detected. 
 
Varied models and organ types have been used to provide evidence for the role of donor 
and recipient lymphatics in allogeneic transplantation.  Disruption of lymphatics resulted 
in delayed rejection or even permanent graft survival in some models. The mechanisms 
involved are complex, and may be independent of leukocyte trafficking. Future research 
focus should concentrate on elucidating the mechanisms involved so that they can be 
harnessed and translated into clinically applicable protocols to prolong allograft survival 
in the clinic.  
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1.1.1 Clinical situation 
For patients suffering end-stage organ failure, transplantation is a life-saving operation. 
Although significant improvements in the short-term survival of allografts have been 
realised in recent years, consistent long-term graft survival remains a clinical challenge. 
One year survival rates for kidney transplants in the UK are currently 94-97%; however, 
this declines to 86-92% after 5 years. For other solid organs such as the heart this figure 
is as low as 71% (1); (Table 1). 
 
Table 1- Clinical transplantation figures for 2016  
(adapted from data available from NHS blood and transplant) (1), (Deceased brain death, DBD; 
deceased circulatory death, DCD) 
 
Organ # registered  # performed 5-year survival 
Heart  248 194 71% 
Kidney 5275 DBD= 1134 
DCD= 851 




Lung 316 DBD= 151 
DCD= 35 
59% 
60% (3 years) 






Currently, rejection of allografts is prevented by the life-long administration of potent 
immunosuppressive drugs. Immunosuppressive therapy for transplant recipients 
comprises two main categories: induction reagents, which aim to reduce the occurrence 
of acute rejection early after transplantation; and maintenance reagents, for preventing 
the development of chronic graft rejection and for treating acute rejection episodes 
throughout the life of the graft. Induction therapy consists of various antibodies that target 




Basiliximab is an Interleukin (IL) 2 receptor antagonist that has shown safety and efficacy 
in multiple clinical trials in renal transplantation patients (2-5). Another induction reagent, 
rabbit anti-thymocyte globulin (ATG), has been associated with the risk of cytokine 
release syndrome and increased infections (6), and is therefore being replaced by other 
agents. Alemtuzumab is an anti-CD52 antibody which targets mature T and B 
lymphocytes and has demonstrated efficacy in pre-sensitized patients (7), although it 
was associated with increased infections. For maintenance therapy, the most effective 
drugs are the calcineurin inhibitors, which target the activation of T cells. Tacrolimus and 
ciclosporin have shown great efficacy in prolonging the survival of renal grafts (8, 9). 
However, the side effects of these drugs which include nephrotoxicity, post-
transplantation diabetes and hypertension, can be severe and thus dosing is carefully 
monitored (10). Another class of immunosuppressive drugs, the mammalian target of 
rapamycin (mTOR) inhibitors, have been introduced in the hope of sparing the use of 
calcineurin inhibitors (11). Sirolimus and everolimus work by inhibiting the regulatory 
kinase, mTOR, which blocks the responsiveness of lymphocytes to IL-2. Although less 
effective at reducing graft rejection (11), these agents are not as nephrotoxic as the 
calcineurin inhibitors. Certain patients may be switched to mTOR inhibitors to avoid the 
long-term use of calcineurin inhibitors (12). However, the mTOR inhibitors can lead to 
development of lympheodema in transplant patients (13) because they impair the 
signalling pathways involved in VEGF-C production and responsiveness (14), which has 
a negative effect on restorative lymphangiogenesis. In addition, Fingolimod (FTY720), 
which is a modulator of the sphingosine-1-phosphate (S1P) receptor, initially showed 
efficacy in pre-clinical models of transplantation. It results in immunosuppression caused 
by inhibition of lymphocyte re-circulation with sequestration of activated lymphocytes 
within lymph nodes, and is efficacious at preventing graft rejection (15). However, its use 
in renal transplant patients was halted because of adverse ocular effects (16). The third 
class of maintenance immunosuppressive drugs are the anti-proliferative agents, which 
provide an additive effect in combination with calcineurin inhibitors (17). Azathioprine is 
a purine analogue which disrupts RNA and DNA synthesis and thus supresses B-cell 
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and T-cell proliferation. Mycophenolic acid, a newer anti-proliferative drug, is a reversible 
inhibitor of inosine monophosphate dehydrogenase, the enzyme used in purine 
synthesis by proliferating T and B cells. Its efficacy has been demonstrated by multiple 
clinical trials (18, 19); however, it is associated with gastrointestinal disturbances and 
leukopenia (17). In addition to the specific immunosuppressive agents mentioned above, 
the majority of transplant recipients receive steroid therapy, typically in the form of 
Prednisolone, which is a synthetic corticosteroid. This provides broad spectrum 
immunosuppression, which is very effective for the prevention of graft rejection. 
However, the use of steroids must be carefully monitored because of adverse side 
effects, including increased blood sugar levels, mood disturbances and weight gain 
(reviewed in (20)). 
 
In our unit, kidney transplant recipients currently receive steroids, tacrolimus and 
mycophenolic acid as standard. Low-risk and standard-risk recipients receive 
Basiliximab as induction therapy and high-risk recipients, such as those with human 
leukocyte antigen (HLA) antibody incompatibility, receive Alemtuzumab. 
 
There is a pressing need for the development of new therapies for the prevention and 
treatment of transplant rejection. With a greater understanding of the biological 
processes involved, scientists and clinicians can develop novel approaches to improve 
the survival of allografts. 
 
 
1.1.2 The immune response to an allograft- mechanisms of rejection 
1.1.2.1 Innate response 
All vascularised transplants are subject to ischemia-reperfusion injury due to the 
transplant procedure. As a result, the innate immune system of the host is stimulated by 
the release of danger associated molecular patterns (DAMPs) from damaged cells, 
which activate Toll-like receptors (TLRs) on cells within the graft. TLR engagement on 
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dendritic cells (DCs) causes them to up-regulate molecules crucial to T-cell stimulation, 
such as CD80 and CD86, and also increases their migratory capacity (21).  
 
Ischemic injury can also activate the complement system. Local production of the 
complement component C3 within the graft has been shown to be essential for graft 
rejection to occur (22), and this is achieved through various mechanisms. There is strong 
evidence that the small peptide fragments, C3a and C5a, mediate dendritic cell activation 
(23), and provide co-stimulatory and survival signals to T cells (24). 
 
 
1.1.2.2 Innate cellular response 
Neutrophils infiltrate allogeneic graft tissue within the first few hours following 
reperfusion; producing cytokines, such as IL-1β, and chemokines, such as CCL1, 2 and 
5, which contribute to the inflammatory environment (25). Blocking neutrophil infiltration 
or function shows an initial beneficial effect and when combined with co-stimulation 
blockade can improve graft survival in animal models (26). 
 
Monocytes are the circulating precursors of dendritic cells and macrophages, and rapidly 
infiltrate inflamed sites. Once within the graft they differentiate into mature DCs or 
macrophages; within days following transplantation the majority of graft DCs are host 
monocyte-derived (27), and these cells can interact with cognate T cells within the graft 
(28). It is also now clear that host-derived monocytes can initiate adaptive immune 
responses via a process termed ‘innate allo-recognition’. Transplantation studies using 
RAG-/-ɣ-/- mice that lack T, B and natural killer (NK) cells showed that grafts in these mice 
are infiltrated with host monocytes, which adopt a mature DC phenotype with high levels 
of major histocompatibility complex (MHC) class II and co-stimulatory molecules. These 
cells were more potent and long-lasting in allogeneic grafts compared with syngeneic 
grafts, indicating that this was a specific allogeneic response (29). By contrast, host 
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myeloid-derived suppressor cells have been described as mediators of tolerance in 
transplant models (reviewed in (30)). 
 
NK cells are known to play a negative role in transplantation in that they promote rejection 
of grafts via the ‘missing self’ theory. This refers to the fact that NK cells recognise a lack 
of MHC class I on the surface of allogeneic cells and become activated leading to release 
of cytokines such as IFN-γ and TNF-α, and cytotoxicity (31). 
However, NK cells have also been demonstrated to dampen the allo-immune response 
(31), and this is attributed to the fact that they rapidly kill donor passenger leukocytes 
within recipient secondary lymphoid organs (32). 
 
It has recently become clear that there is a distinct interplay between the innate and 
adaptive immune systems following transplantation, and there is evidence suggesting 
that adaptive immune responses, in particular T cell responses, are limited or lacking in 
the absence of innate immune activation (33, 34). The innate immune system plays a 
critical role in graft rejection not only by providing initial danger signals to immune cells 
in the graft (23), but also by providing crucial co-stimulatory signals to T cells (24).  
 
 
1.1.2.3 Antibody-mediated rejection 
Antibody-mediated rejection can cause acute or chronic injury to the graft and in some 
cases leads to complete graft loss. The antibodies which cause this type of injury can be 
targeted towards donor HLA molecules, endothelial cell antigens, or ABO blood group 
antigens present on red blood cells and endothelial cells.  
 
Acute antibody-mediated rejection can occur within days after transplantation and can 
be triggered by either preformed or de novo generated donor-specific antibodies. It is 
characterised by deposition of the complement component C4d in the graft, and occurs 




Chronic antibody-mediated rejection is often the result of donor-specific antibodies that 
collect in the graft and are deposited on capillary endothelium. In the case of kidney 
grafts this injury is observed histopathologically as glomerulopathy characterised by 
endothelial hypertrophy and fibrillary deposition. 
 
 
1.1.2.4 T cell-mediated rejection 
Allo-reactive T cells can be activated by various mechanisms, all of which involve the 
recognition of non-self antigens; therefore the T cell response is referred to as allo-
specific. Allo-reactive CD4+ T cells differentiate upon stimulation into various subtypes 
each of which has a different set of effector functions (reviewed in (36)), and is capable 
of causing graft rejection in isolation (37, 38). 
 
T helper (Th) 1 cells produce the cytokines interferon gamma (IFN-ɣ) and IL-2, which 
help in the; priming of cytotoxic T cells (CTL), and the production of IgG2a by B cells 
leading to complement activation, both of which are implicated in graft rejection. Although 
the Th1 response is traditionally considered pro-inflammatory, recent evidence has 
suggested that IFN-γ plays a regulatory role in the allo-response, supporting Treg 
development and dampening Th17 responses (39). 
 
Th17 cells produce IL-17, IL-21 and IL-22 which act to recruit neutrophils and 
macrophages to the graft (40). Th17 cells are mainly implicated in the early post-
transplantation period and many studies have found increased levels of IL-17 in acutely 
rejecting grafts (41). In addition, neutralization of IL-17 has also shown beneficial effects 
in animal models of transplantation (42). 
 
Th2 cells produce the cytokines IL-4, IL-5, IL-9, IL-10 and IL-13, which aid B cell 
activation and recruitment of eosinophils, promoting rejection. There is experimental 
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evidence linking expression of Th2 cytokines and eosinophil infiltration of grafts (43). 
Additionally, in vitro Th2 polarized cells adoptively transferred into immunodeficient mice 
can cause acute allograft rejection (44).  
 
Allo-reactive CD8+ T cells function as CTLs and kill graft cells via perforin and granzyme 
B, or Fas and Fas ligand-dependant pathways. Cytotoxic CD8+ T cells with a memory 
phenotype have proven to be a barrier to tolerance induction in experimental models 
(45).  
 
Memory T cells produce a fast and effective allo-response. This is because they respond 
to lower concentrations of antigen, and have a smaller need for co-stimulation in order 
to produce effector functions. The reason for this may be because memory cells do not 
require multiple rounds of cell division before producing cytokines (46). Additionally, 
there is evidence that memory cells can circumvent the conventional trafficking pathways 
of naïve T cells and become activated regardless of lymph node occupancy (47). These 
properties of allo-reactive memory cells make them resistant to tolerance induction 
protocols (48). Many studies have found a correlation between the presence of allo-
reactive memory T cells before transplantation and the occurrence of rejection episodes 
in human transplant recipients (reviewed in (49)). 
 
 
1.1.3 The immune response to an allograft- allo-recognition 
Recipient T cells need to be primed with allo-antigen before acquiring graft destructive 
capabilities, and this can occur via three pathways of allo-recognition: the direct, indirect 
and semi-direct. In the direct pathway, which predominates in the early acute phase of 
the allo-response, foreign MHC-expressing cells are directly recognised by recipient T 
cells. Contrary to this, the indirect pathway involves the presentation of donor peptides 
to cognate T cells by self MHC-expressing antigen presenting cells (APC). Cross-talk 
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between the two pathways can also occur when MHC-peptide complexes are transferred 
between donor and recipient APC in the semi-direct pathway. 
 
 
1.1.3.1 The direct pathway 
The direct pathway of allo-recognition was first demonstrated in the mixed leukocyte 
reaction (MLR), where leukocytes from two genetically different individuals were co-
cultured, resulting in a significant increase in cell activation compared with co-cultures 
from genetically identical individuals (50). These results were further validated in vivo in 
rodent models of allogeneic transplantation, and the strength of the response was 
attributed to the presence of donor passenger leukocytes (DPL). DPL are leukocytes 
present within the graft tissue which are transferred to the recipient at the time of 
transplantation, and recognised by T cells via the direct pathway. The contribution of 
DPL to the rejection process was determined in studies by Lechler et al., where grafts 
were ‘parked’ in temporary hosts to deplete DPL, prior to transplantation. These grafts 
survived longer than non-depleted grafts, and the survival could be reversed by the 
addition of donor strain DCs (51). 
 
DPL leave the graft rapidly after transplantation and traffic to the secondary lymphoid 
organs (SLO) of the recipient, namely the spleen and local draining lymph nodes (52). 
Here they come into contact with T cells that directly recognise the MHC on their surface 
as foreign. The potency of the direct pathway lies in the fact that a large proportion of the 
T cell repertoire can react to foreign MHC-peptide complexes; and there are two 
proposed models to explain this phenomenon. Firstly, the ‘peptide-centric’ model states 
that it is the diversity of the allo-peptides presented in the context of donor MHC that 
drives the intense direct allo-response, rather than the MHC molecule itself. As donor 
APC will be presenting a plethora of different peptides, multiple T cell clones can be 
activated. This has been proved to some extent by the co-culture of T cells with 
allogeneic APC lacking peptide, which led to limited T cell responses (53, 54).  
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By contrast, the ‘MHC-centric model’ proposes that the observed alloreactivity of DPL is 
due to structural differences between self and allo-MHC molecules; single amino acid 
polymorphisms found in the allo-MHC may drive recognition by the T cell receptor (TCR). 
These interactions may also be higher affinity than self MHC-TCR interactions. In 
addition, it is likely that the high density of MHC molecules expressed by DPL enhances 
the response (55). Evidence for this model comes from studies where alterations in the 
TCR binding site of allo-MHC molecules led to perturbations in binding and subsequent 
effector functions (56). 
 
 
The direct pathway produces an intense T cell response directed at the graft that is short-
lived and levels off a short time after transplantation. It is known that DPL are rapidly 
killed within recipient SLO by NK cells which recognise them as foreign due to their lack 
of self-MHC (32), and are only identifiable in SLO for a short time following 
transplantation (57, 58).  Immunosuppressive therapy inhibits directly-activated T cells 
and prevents acute rejection in transplant recipients (59). 
 
 
1.1.3.2 Donor passenger leukocytes 
Since the description of the passenger leukocyte theory of direct allo-reactivity, attempts 
have been made to deplete donor organs of passenger leukocytes either before or after 
transplantation, in order to prolong survival in allogeneic recipients. Irradiation of donors 
prior to transplantation is one method of removing passenger leukocytes and has proved 
successful in prolonging survival of grafts in animal models of transplantation (60, 61); 
however, this is not a feasible strategy for clinical transplantation. Passenger leukocytes 
can also be removed by ex vivo perfusion of the organ before transplantation, and this 
has shown some efficacy in animal models (62). Pharmacological depletion of DPL has 
been studied, and efficacy has been shown in animal transplantation models with the 
use of anti-MHC class II antibodies (63, 64); however, there were issues with specificity 
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and whether or not the target cells were depleted. In addition, a study by Goldberg et al. 
reported the use of anti-CD45 antibodies in human renal transplantation, which were 
perfused into donor kidneys before transplantation, and showed efficacy in diminishing 
rejection episodes for patients (65). Recent work from our laboratory has demonstrated 
the effectiveness of a donor MHC class II-specific immunotoxin in a mouse kidney 
transplantation model, where donor cells were specifically killed and grafts survived 
indefinitely with normal function, reduced donor-specific antibody formation, and delayed 
rejection of third party skin grafts (66). This provides evidence for the efficacy of therapies 
aimed at the immune system of the donor rather than the recipient, and could be an 
approach to limit the use of systemic immunosuppression in the clinic. 
 
 
1.1.3.3 The indirect pathway 
The indirect pathway of allo-recognition refers to the concept that recipient APCs can 
uptake and process donor antigens for presentation to T cells within the context of self-
MHC molecules. This was first evidenced in vitro for donor MHC class I peptides 
presented to CD8+ cytotoxic T cells in the context of self MHC class I on recipient APCs 
(67), followed by in vivo studies leading to direct evidence of presentation of donor MHC 
class II peptides in the context of recipient MHC class II, and activation of a donor-specific 
CD4+ T cell response (68-70). 
 
The initial T cell response following indirect activation is oligoclonal in that it involves a 
limited number of T cell clones, recognizing ‘dominant’ peptides. However, this changes 
throughout the life of the allograft and previously uninvolved T cells can become 
activated by recognition of ‘cryptic’ donor-derived peptides. Benichou and colleagues 
have demonstrated this phenomenon in transplant recipients and found that new clones 
of T cells can become activated by recognition of allo- and also auto-peptides in 
response to inflammatory signals such as IFNɣ (71). In this way, not only is the indirect 




As mentioned previously, most human allografts are protected from acute rejection by 
immunosuppressive therapy; however, many still succumb to chronic rejection. The 
indirect pathway of allo-recognition is heavily implicated in the progression of chronic 
rejection, and has been shown to be sufficient to cause chronic rejection in various 
animal models. In particular, presentation of donor MHC-derived peptides by recipient B 
cells is key to the pathogenicity of chronic rejection, and key studies have shown that 
when this interaction is blocked, graft survival is prolonged due to diminished allo-
antibody production and limited CD4+ T cell responses (72).  
 
It is also now certain that regulatory T cell (Tregs) with indirect specificity are key to 
tolerance induction in a variety of animal transplantation models (73, 74), and that 
regulatory responses are enhanced when the indirect pathway is the dominant 
contributor to alloreactivity (75). 
 
 
1.1.3.4 The semi-direct pathway, MHC transfer and exosomes 
The semi-direct pathway of allo-recognition relies on the fact that leukocytes exchange 
cell surface molecules. This pathway describes recipient APCs presenting both donor 
allo-peptides in the context of self MHC (indirect presentation), and intact donor MHC 
molecules acquired from DPL or graft endothelial cells. The exchange of MHC molecules 
can occur via cell-cell contact, nanotubes, or the release of extracellular vesicles such 
as exosomes. 
 
Although this pathway of allo-recognition has only recently been discovered, the 
evidence for its occurrence in transplantation is indisputable. The paper by Brown et al. 
showed extensive exchange of MHC class II molecules between donor and recipient 
APCs in mouse models of kidney and heart transplantation; these double positive cells 
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expressed co-stimulatory molecules and so were likely to influence the allo-response 
(76). 
 
More recently a paper by Smyth et al. has described the semi-direct pathway as the 
major contributor to CD8+ cytotoxic T cell responses in a skin transplantation model. 
Transfer of donor MHC class I to recipient DCs occurred for at least one month following 
transplantation and T cells activated via the semi-direct pathway contributed to the allo-
response in vivo (77). This paper highlighted the importance of targeting both indirectly 
and directly activated T cells to prolong graft survival and induce tolerance. 
 
Work from Benichou and colleagues (58) and Morelli and colleagues (57) has recently 
provided the first evidence for the role of donor-derived exosomes in the allo-response. 
Their work using both skin and heart transplantation models provides evidence for the 
fact that DPL, and likely graft endothelial cells, release exosomes containing MHC 
molecules and co-stimulatory molecules, which are taken up by recipient APCs within 
draining lymphoid organs. These ‘cross-dressed’ APCs are then able to elicit an allo-
immune response via the semi-direct pathway. Interruption of the exosome release 
pathway prolonged graft survival, and cross-dressed cells isolated from transplant 
recipients initiated proliferation of allo-reactive CD8+ T cells ex vivo. These papers 
support the idea that a relatively small number of DPL can elicit a potent immune 
response in transplant recipients, and this is at least in part due to the release of 
exosomes from DPL resulting in a larger pool of APCs presenting donor MHC for T-cell 
activation. Although interesting, these new findings fail to demonstrate how exosomes 
released from DPL and graft endothelial cells traffic to the spleen and lymph nodes where 
the T cell response is initiated. It is still unclear whether the exosomes are released by 
DPL within the graft and enter the lymphatic system for traffic to SLO, or whether they 
are released upon entry into lymphoid tissue. These are vital questions which need to be 






The key objective of much research in the area of transplantation is the induction of 
donor-specific tolerance in transplant recipients. This means that the foreign graft is 
tolerated by the recipient in the absence of long-term conventional immunosuppressive 
therapy, without graft function being compromised.  
 
Immune tolerance is essential to prevent reaction of the immune system to self-antigens 
(auto-antigens). This is achieved by two distinct mechanisms. Central tolerance occurs 
in the thymus, the location of T cell development, where only cells that recognise auto-
antigens with low avidity are selected for subsequent maturation and release from the 
thymus. However, this process is not entirely efficient and some auto-reactive cells will 
be released into the periphery. Therefore, there is a requirement for suppression of these 
cells to avoid the development of auto-immunity. Tregs, generated either in the thymus 
(natural), or in the periphery from CD4+ T cells (inducible), are able to suppress auto-
immunity, and restrain responses against bacterial and viral antigens, as well as 
restricting transplant rejection and tumour immunity. DCs are also crucial for peripheral 
tolerance as they take up and process antigen from apoptotic cells, and present it to 
Tregs to induce their maturation. 
 
Methods to induce tolerance to an allograft are therefore aimed at either central or 
peripheral tolerance mechanisms. Central tolerance to an allograft has been achieved in 
non-human primate models by the induction of mixed chimerism prior to transplantation. 
This refers to the presence of both donor and recipient bone marrow cells in the recipient. 
Mixed chimerism is achieved by hematopoietic bone marrow transplantation with pre-
conditioning of the recipient to allow engraftment of donor cells. Although this method of 
transplantation tolerance induction has proved successful in pre-clinical models, its use 
in humans is limited by the ethics of myeloablative pre-conditioning; however, trials in 




Induction of peripheral tolerance to an allograft is a much safer approach for transplant 
patients; however, unanswered questions remain. There is strong evidence from rodent 
models that tolerance to an allograft can be achieved by the adoptive transfer of Tregs 
(reviewed in (79)), and the use of this cell type has recently moved into the clinic with 
several trials underway (80). Transplantation tolerance can also be induced by immature 
DCs, which present donor antigen without sufficient co-stimulation, leading to T-cell 
tolerance. Research in this area is focused on optimising protocols to maintain DCs in 
an immature state to reduce allo-reactive T-cell stimulation and induce tolerance. In 
addition, regulatory macrophages, which produce the anti-inflammatory cytokine IL-10 
and induce Th2 responses, have recently been identified in mice and humans and show 
promise for tolerance induction in the clinic (81).  
 
Many transplantation tolerance induction protocols have the potential to decrease the 
use of immunosuppressive drugs in transplantation patients; however, much research 
remains needed to assess the effectiveness of adoptive cell therapy, and to improve the 
safety of mixed chimerism induction. 
 
 
1.1.5 T-cell co-stimulation 
It was initially believed that TCR engagement with MHC was sufficient to induce 
activation of naïve T cells; however, experiments with primary T cell cultures proved that 
for optimal activation a second signal is required. This second signal comes from co-
stimulatory molecules expressed by T cells binding to ligands on APCs. CD28 is the 
putative co-stimulatory molecule expressed by all T cells, and in the absence of signalling 
through CD28 T cells undergo anergy whereby they become unresponsive to antigen 
(82). The ligands for CD28 are CD80 and CD86, which are upregulated on APCs during 
inflammation. CD152 expressed on T cells can also bind CD80 and CD86 although with 
very different functional outcomes. CD152 is known as a co-inhibitory molecule as its 
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engagement leads to down-regulation of CD80 and CD86 on APCs and thus a 
dampening of the immune response. Approaches for blocking co-stimulation in 
transplantation models have used CTLA-4Ig with success (83). This has now been 
developed into a clinical strategy with the development of Belatacept, a CTLA-4Ig drug 
available for human use that has been used as immunosuppressive therapy for renal 
transplantation patients (84). 
 
CD40 and its ligand CD154 are essential co-stimulatory molecules for the effective 
generation of high affinity isotype-switched antibodies. CD40/CD154 interactions are 
also important for DC survival, proliferation of B cells and activation of some antigen-
specific T cells. Efforts to translate anti-CD154 therapy into the clinic was unfortunately 
halted, despite promising results in pre-clinical models, due to the expression of CD154 
on activated platelets which led to adverse thromboembolic effects in treated individuals 
(85).  
 
The programmed death (PD) 1 receptor is expressed on many cells of the immune 
system including NK cells and some DCs, and binds the ligands PDL1 and PDL2. It is 
not constitutively expressed on T cells but is up-regulated following activation, and 
ligation leads to down-regulation of T cell effector cytokines such as IFN-γ, TNF-α, and 
IL-2. This pathway has also shown importance in transplantation with PD1 knock-out 
recipients overcoming co-stimulation blockade-induced tolerance (86). As yet there are 
no reagents available for the activation of PD1 in humans, although recent efforts to 
switch off this pathway for the treatment of cancer have demonstrated its importance in 
human immune responses (87). 
 
 
1.1.6 The importance of cell trafficking in transplantation 
All of the pathways mentioned above require the activation of recipient T cells by APCs, 
for the initiation of graft rejection. In this context the APCs are most likely DCs of myeloid 
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lineage; although plasmacytoid DCs have also been implicated (88). As both the number 
of APCs and cognate T cells are low, specialised niches are required for them to 
encounter each other for an effective allo-immune response. It was originally thought 
that, in the case of fully-vascularised solid organ transplants, allo-sensitisation only 
occurred in the graft itself. A pivotal paper by Larsen et al. (52) first described an 
alternative route involving trafficking of donor-derived DCs from the graft to the spleen 
for interaction with CD4+ T cells. Contrary to this, the rejection of allogeneic skin grafts is 
dependent on the presence of local draining lymph nodes (DLN) (89); until recently the 
role of DLN in the allo-response to fully vascularized solid organ grafts had not been 
investigated.  
 
A paper from Lakkis and colleagues demonstrated that mice lacking SLO failed to reject 
fully allogeneic heart grafts, and it was concluded that the lymph nodes and spleen 
provided the correct niche for interactions between APCs presenting donor antigen and 
recipient T cells, and that when absent recipient T cells were ‘ignorant’ to the presence 
of allo-antigen (90). However, the evidence presented in this paper has been disputed. 
It has been suggested that the aly/aly mice used in the study have a fundamental defect 
in antibody isotype switching and T cell homing, and this may explain the observations 
rather than the lack of lymph node tissue (91). This implies that a greater understanding 
of the mechanisms of immune cell trafficking between the graft and lymphoid tissue of 




1.2.1 Introduction to the lymphatic system 
The lymphatic system is the second circulatory system of the body, and is responsible 
for drainage of interstitial fluid from peripheral tissue back to the blood vasculature. In 
addition to its role in fluid homeostasis, the lymphatic system forms a vital network of 
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conduits for efficient trafficking of the cells and molecules of the immune system. This 
section will outline the physiological function of the lymphatic system, its development, 
and its dysfunction in disease.  
 
 
1.2.2 Historical perspective 
Although it was Hippocrates ‘the father of medicine’ who first described the presence of 
lymph nodes and chyle in humans in the 5th century BC, it wasn’t until much later, in the 
16th century, that the Swedish intellectual Olaus Rudbeck explained the proper structure 
of the lymphatic system. Helped by the discovery by William Harvey of the blood 
circulatory system, Rudbeck correctly observed that fluid in lymphatic vessels drained 
away from tissue and converged at the thoracic duct, where it re-entered circulation via 
the blood. He also described the presence of valves in the large lymphatic vessels. The 
most comprehensive study of the human lymphatic system was published in 1938 by the 
French anatomist Rouviere. This was a continuation of the work of Sappey, who had 




1.2.3 Development of the lymphatic system 
For many years the embryonic origins of lymphatic vessels had been debated, and it 
wasn’t until the discovery of the transcription factor Prox1 that mouse studies confirmed 
a vascular origin for the lymphatic system (93). When Prox1 was knocked out in mice, 
embryos did not survive past day E15 and were found to lack lymphatic vessels (94). 
Prox1-positive cells were found to migrate from the embryonic veins and form sprouting 
lymphatic vessels (95). Work then moved to finding the signalling pathway for this 
sprouting mechanism, and it was discovered that vascular endothelial growth factor 
(VEGF) C signalling via VEGFR3 is crucial for lymphatic endothelial progenitor cell 
migration from the veins (96). After migration from the veins, sprouting lymphatic 
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endothelial progenitor cells form lymph sacs which develop further into mature lymphatic 
vessels (97). Later in development of the mouse embryo, clusters of Prox1-positive cells 
have been observed in tissue such as skin (98) and heart (99), and lineage tracing 
experiments using inducible knockout mice have demonstrated a non-venous origin for 
these cells, which can migrate and proliferate to form lymphatic vessel networks within 
tissues. 
 
For the blood and lymphatic systems to function properly they need to be mostly 
separated, to avoid entry of blood into lymph but to allow passage of lymph into blood. 
This is achieved by specialised lymphatic valves which develop at the junction of the 
thoracic duct and the jugular vein, the point where lymph drains into the blood circulation. 
Again Prox1 is key to this process, and Prox1 heterozygous mice have defective valves 
(100). Lymphatic valve development and maintenance are highly co-ordinated 
processes which are tightly controlled through specific signalling pathways, which will be 
discussed in detail later.  
 
The adult lymphatic system consists of a hierarchical network of vessels, starting with 
the initial lymphatics (sometimes termed lymphatic capillaries) within tissue parenchyma, 
leading onto pre-collector then collector vessels which converge at the thoracic duct. 
There are two main processes involved in development of the lymphatic vessel network 
beyond the lymph sac: recruitment of smooth muscle cells and pericytes, and lymphatic 
valve formation. Recruitment of smooth muscle cells seems to be dependent on the 
extracellular matrix protein Reelin which is released from lymphatic endothelial cells 
(LECs) upon contact with smooth muscle cells (101). Valve formation and vascular 
remodelling in pre-collector and collector vessels is controlled by the EphB4/ephrin B2 
and angiopoietin/Tie axes (102). 
 
The interaction between macrophages and lymphatic endothelial cells has been 
highlighted in lymphatic remodelling in disease settings, which will be discussed later, 
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but there is also evidence that macrophages interact with lymphatic endothelial cells 
during embryogenesis. It has been found that macrophages provide essential growth 
and patterning signals to developing lymphatic vessels in the form of VEGF-C (103). 
 
 
1.2.4 Physiological role of the lymphatic system 
The lymphatic system carries out the vital function of draining proteins and cells from the 
interstitium of tissues which are too large to be absorbed by the blood capillary network. 
The majority of peripheral organs and tissue contain lymphatic vessels through which 
fluid containing cells and proteins can drain and be transported back to the blood 
circulation in a uni-directional flow. Lymph from the lower half of the body and the left 
upper half drains directly into the thoracic duct which empties into the blood at the 
junction of the left jugular vein and left subclavian vein; whereas lymph from the right 
upper half of the body drains into the right lymph duct which enters the blood at the right 
jugular and right subclavian vein. As well as draining proteins and cells from peripheral 
tissues, the lymphatic system plays a role in nutrient absorption in the gut, particularly 
the absorption of dietary fats. 
 
The rate of lymph flow from the periphery is controlled by the rate of leakage of proteins 
from the blood network into the interstitium. As the interstitial protein concentration 
increases, the osmotic force causes fluid to move from the blood into the tissue. This 
increase in fluid pressure causes the lymphatic capillaries to open at the junctions 
between lymphatic endothelial cells to allow fluid to enter the vessel. The pressure inside 
the capillary then increases causing the junctions to close and lymph to flow away from 
the tissue. Therefore, eventually the transport of fluid away from the tissue by the 
lymphatics balances out the effect of leakage from the blood vessels, and homeostasis 





1.2.5 Disorders of the lymphatic system 
The understanding of how defective lymphatic vessel function can cause or exacerbate 
human disease is improving. The most notorious lymphatic vessel disorder is 
lymphoedema; a common condition with multiple and complex aetiology. It can be the 
result of genetic abnormalities affecting lymphatic vessel function, or be secondary to 
lymphatic vessel insult. The disease is characterized by the disproportionate 
accumulation of interstitial fluid, and in chronic cases can be aggravated by fibrosis, 
adipose deposition and inflammation. There are currently no treatments aimed at curing 
the disease; and therapies aim to relieve pain and disability. However, new insights are 
being made into the genetic basis of primary lymphedema, and the importance of the 
VEGF-C/VEGFR3 signalling pathway has been highlighted, with many components 
being mutated in affected patients (105). 
 
Also there is now known to be a definite link between cardiovascular disease and 
lymphatic vessel function. The heart has a high density of lymphatic vessels, which show 
a proliferative response to myocardial infarction, atherosclerosis, and infectious disease 
(106). However, data from mouse models have shown that the promotion of lymphatic 
vessel proliferation using pro-lymphangiogenic factors such as VEGF-C improves 
resolution of damage caused by myocardial infarction (99). So the proliferation of LECs 
in this case may be a protective response. 
 
It is also interesting to note the emerging link between lymphoedema and obesity. In 
Prox1 heterozygous mice, lymph containing pro-adipogenic factors leaks from 
dysfunctional lymphatic vessels and leads to the development of obesity (107). This 
coincides with long-standing clinical observations of lymphoedema patients suffering 
from obesity (108).  
 
In conclusion, a greater understanding of how lymphatic vessels function, and the 
signalling pathways involved in the proliferation and maintenance of vessels, is leading 
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to the development of new therapies for patients suffering from diseases caused by 
lymphatic vessel dysfunction. 
 
 
1.2.6 Structure of the lymphatic system 
In contrast to the blood circulatory system, the lymphatic system is linear. This means 
that lymph containing interstitial fluid, large extracellular molecules and cells drains from 
tissue and organs into initial lymphatics, moves through to larger collecting vessels which 
are interconnected with lymph nodes, and is eventually returned to the blood system via 
the thoracic duct. The hierarchical structure of the lymphatic system is key to its function. 
 
 
1.2.6.1 The initial lymphatics 
The initial lymphatics, sometimes referred to as lymphatic capillaries, are blind-ended 
vessels found in nearly all vascularised tissue, and express high levels of the lymphatic 
vessel endothelial hyaluronan receptor 1 (LYVE-1). Typically they are 30-80µm in 
diameter and comprise a single layer of LECs with no basement membrane. Unlike the 
structure of blood capillaries, the LECs making up initial lymphatics are joined together 
by dis-continuous ‘button like’ junctions, which make the vessels extremely permeable 
to fluid and cells (109). The LECs are connected to the extracellular matrix of tissue by 
anchoring filaments that are in turn attached to collagen fibres (110). These fibres tighten 
in response to tissue swelling, which causes the lymphatic vessel to open and fluid to 
enter the lumen. From here lymph moves into pre-collector vessels, which are 
surrounded by a thin layer of smooth muscle cells. 
 
 
1.2.6.2 The collecting lymphatics 
The pre-collector vessels drain into collecting lymphatics which are vessels specialized 
for the transport of lymph rather than drainage from tissue. Collecting lymphatics are 
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characterized by the presence of a basement membrane, a defined layer of smooth 
muscle cells, and continuous ‘zipper-like’ junctions (109). The action of the associated 
smooth muscle cells and surrounding skeletal muscle propels the lymph in uni-directional 
flow towards re-circulation. The collecting lymphatic vessels from distinct segments, 
called lymphangions, separated by valves which open and close in a co-ordinated 




Figure 1.1- The hierarchical structure of the lymphatic system.  
Blind-ended lymphatic capillaries in tissue are composed of oak leaf-shaped LECs with button-
like junctions to allow for efficient drainage of fluid and cells. Collecting lymphatics are 
accompanied by a smooth muscle cell layer and contain frequently spaced valves to prevent 
backflow of lymph. 
 
 
1.2.6.3 Lymphatic valves 
Lymphatic valves are essential to prevent the retrograde flow of lymph back into tissue, 
and indeed patients with lymphedema have been found to have genetic abnormalities in 
key pathways of lymphatic valve development and maintenance (111).  
 
Recent elegant studies in the mouse have elucidated the mechanism of how lymphatic 
valves form during embryogenesis and in early life (reviewed in (112)). Firstly, there is 
clustering of LECs at branch points of lymphatic capillaries, which coincides with up-
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regulation of the transcription factors Prox1 and Foxc2, as well as down-regulation of 
LYVE-1 expression. These cells then develop an elongated morphology and re-arrange 
their cell-cell junctions, and eventually form a protrusion into the vessel lumen. This 
process is dependent on expression of the adhesion molecule receptor, integrin-α9, 
which allows for proper arrangement of the extracellular matrix at the edges of the LEC 
protrusions. Mice deficient in integrin-α9 fail to develop fully elongated valve leaflets, and 
missense mutations in human foetuses causes a lethal phenotype (113). Maturation of 
the valve is then controlled by various signalling pathways including ephrin B2-eph4 
(114), angiopoietin2-Tie2 (115) and phosphoinositide (PI) 3 kinase-protein kinase B 
(116). Mutations in the PDZ cytoplasmic domain of ephrin B2 result in embryonic lethality 
characterized by chylothorax due to inhibition of lymphatic drainage into the thoracic duct 
(102). EphrinB2-eph4 signalling has also been shown to play an essential role in 
lymphatic and blood vessel angiogenesis. A link between the ephrin B2-eph4 and 
VEGFR3-VEGF-C pathways was found by Wang et al. Stimulation of cultured LECs with 
recombinant ephrin B2 led to internalisation of VEGFR3, which is required for down-
stream signalling, and this process was compromised in ephrin B2 knock-out cells (117). 
 
 
1.2.6.4 Additional roles of ephrins in immunity 
In addition to the role that the eph/ephrin signalling pathway plays in lymphatic 
development and maintenance, it has more recently become implicated in other settings. 
The eph family of neuronal guidance molecules and their ligands, the ephrins, are the 
most abundant group of receptor tyrosine kinases in the mammalian genome. The role 
they play in embryogenesis and cancer pathology has been well established; however, 
they are now being implicated in inflammation and immunity. Expression of ephs and 
ephrins across cell types is varied, and signalling can occur either through the receptor 




Eph/ephrin signalling most commonly results in changes in cell motility; either repulsion 
or adhesion of cells to guide in the organisation of cells in developing tissue, or during 
de novo growth such as in lymphangiogenesis (102). In addition to patterning responses, 
signalling via the eph/ephrin pathway can affect cell differentiation, proliferation and gene 
expression (118), further indicating a potential role in chronic inflammation. 
 
Enhanced expression of ephrin B2 has been found on the blood endothelium in areas of 
atherosclerotic plaque formation, where it was found to aid adhesion and transmigration 
of infiltrating monocytes which express the ephB4 receptor (119). Also, addition of 
immobilized ephrin B2 to monocytes in culture caused them to upregulate expression of 
chemokine (c-c motif) ligand (CCL) 21 (119). In fact, many leukocytes express ephrins, 
and have been found to modulate their expression in response to pro-inflammatory 
signals such as TNF-α (120). In particular, ephrin B2 has been demonstrated as a co-
stimulatory molecule for T cells (121). In the study by Yu at al. ephrin B2 mRNA was 
found to be expressed in the white pulp of the spleen and the cortex of the thymus. At 
the protein level it was found to be expressed on the surface of T cells and monocytes, 
whereas its receptors were mainly found on T cells. T-cell stimulation could be induced 
using solid phase ephrin B2 and sub-optimal amounts of CD3. This led to the production 
of IFN-γ and enhanced cytotoxic activity of CD8+ T cells. Evidence was also provided for 




1.2.7 Lymphatics and immunity 
Recently, it has become more fully appreciated that the lymphatic system plays an 
essential role in immunity (122). The structure of the system, with drainage from the 
interstitium to the lymph nodes and back into blood circulation, means that antigens in 
the periphery are transported to the sites were they can be recognised effectively by cells 
of the adaptive immune system. The lymph nodes provide a perfect niche for interactions 
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between APCs and T and B lymphocytes, and once activated, lymphocytes are guided 
out of the lymph nodes, also via lymphatic vessels, back towards blood circulation where 
they can access the peripheral sites where the antigen is present. Lymphatic vessels are 
ideally suited to the function of transporting APCs to the draining lymph nodes under 
inflammatory conditions, reacting promptly to inflammatory stimuli to change surface 
expression of adhesion molecules and thus allowing co-ordinated migration of APCs to 
the site of T-cell activation. 
 
Lymphatic vessels also show a proliferative response in immune reactions, and via a 
process called lymphangiogenesis, vessels expand in size and number in sites where 
there is an ongoing immune response. The exact function of this lymphatic response is 
unknown, and it seems to be dependent on whether the prevailing conditions are pro- or 
anti-inflammatory.  
 
In this section, the mechanisms of immune cell trafficking through lymphatics, and the 
process of lymphangiogenesis, will be discussed in detail, with relation to their influence 
on the immune response following transplantation. 
 
 
1.2.7.1 Leukocyte trafficking 
DCs are known to be the most potent APCs of the immune system, and much of the 
work towards elucidating the mechanisms of lymphatic transmigration has therefore 
used DCs. In homeostasis, DCs continue to migrate from the periphery to the DLN in 
order to present self-antigens. This is crucial for the maintenance of tolerance to self, 
and indeed mice lacking lymphatic vessels develop severe autoimmunity due to a defect 
in the homeostatic transport of DCs (123). Under steady-state conditions, DCs move in 
an amoeboid fashion towards the lymphatic vessel in an integrin-independent process 
(124, 125), that requires a chemotactic chemokine gradient (126). The chemokine-
receptor pair crucial for lymphatic migration of DCs is CCL21, which is produced by 
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LECs, and CCR7, which is expressed by DCs. DCs then enter the lymphatic vessel at 
portals, which are areas between LEC adherens junctions where basement membrane 
is least dense (127). From here they move inside the vessel in the direction of lymph flow 
towards the collecting vessel and ultimately enter the DLN. 
 
Under inflammatory conditions, the extra-cellular matrix of the interstitium is not 
conducive to the amoeboid movement of DC due to loosening of the collagen fibres 
(128). Therefore, entry of DC into the lymphatic vessel lumen becomes an active process 
dependent on integrins, particularly intercellular adhesion molecule (ICAM) -1 (Figure 
1.2). The seminal paper by Johnson et al. showed that DC transmigration across the 
lymphatic endothelium in inflammatory conditions was dependent on ICAM-1, and that 
this process could be blocked in vitro by administering anti-ICAM-1 antibodies (129). In 
inflammation, movement of DCs towards the vessel is still dependent on a CCL21 
chemokine gradient, and in fact LECs increase secretion of CCL21 following an 
inflammatory stimulus (130). As interstitial flow increases toward the lymphatic vessel, 
more CCL21 is needed to maintain the gradient in favour of guiding DCs towards the 
vessel. CCL21 is also able to bind to heparan sulphates within the extra-cellular matrix 
in order to prevent it being washed away by the flow of fluid in the opposite direction 
(131). In addition, it has been found that migration of immune cells to DLN is unaffected 
when lymphatic vessels are sparse, even if flow is dramatically decreased, because the 
CCL21 gradient becomes more favourable (132). Again DCs then enter the lymphatic 
vessel lumen at portals where basement membrane is least dense. It is apparent that 
DC migration through lymphatics under inflammatory conditions is an active process 
involving co-ordinated up-regulation of various molecules by LEC and DC, which is 
crucial for recruitment of DC from the interstitium towards the vessel and also for 






Figure 1.2- Active transmigration of leukocytes across lymphatic endothelium during 
inflammation.  
Under normal conditions DCs move in amoeboid fashion and enter lymphatic vessels at portals, 
and traffic to draining lymph nodes. During inflammation, collagen fibres loosen and DCs require 
integrin binding (namely ICAM-1 to its receptor LFA-1) to enter lymphatic vessels. 
 
 
LECs express a crucial immune regulatory molecule called D6 that scavenges excess 
inflammatory chemokines, preventing lymphatic congestion and facilitating resolution of 
inflammation. Inflammation is exacerbated when this molecule is absent (133). 
 
As mentioned previously, initial lymphatics express high levels of LYVE-1, and indeed 
this molecule is often used exclusively as a marker for lymphatics (134). LYVE-1 is a 
receptor for hyaluronic acid (HA) and is crucial for lymphatic uptake of HA from the 
interstitium and transport to the lymph node for degradation (135). The presence of HA 
fragments has been implicated in transplant rejection, and in a model of lung 
transplantation increased lymphatic vessel density was correlated with greater clearance 
of HA from the graft and improved survival (136). It is also true that LYVE-1 is involved 
in adhesion of DCs and macrophages to the lymphatic endothelium (137); however, 
more research is needed to fully elucidate the role of LYVE-1 in lymphatic transport. 
 
The fact that under inflammatory conditions LECs actively recruit DCs from within tissue 
interstitium for mobilization to lymph nodes means that the lymphatic vessels of the donor 
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and the recipient could potentially play a role in the immune response following 
transplantation (Figure 1.3). Indeed, LECs express TLR4 which as mentioned previously 
is a receptor for DAMPs and has been heavily implicated in ischemia-reperfusion injury 
following transplantation (138). Activation of TLR4 on LECs leads to activation of the 
transcription factor NF-κB (139), which leads to up-regulation of inflammation-associated 
molecules including ICAM-1 (140). In this way, inflammation-induced activation of the 
lymphatic endothelium within graft tissue could promote migration of donor-derived DCs 
to the DLN where they would activate recipient T cells via the direct pathway of allo-




Figure 1.3- Proposed mechanism of lymphatic vessel activation following transplantation.  
(1) Inflammation caused by ischemia reperfusion releases TLR ligands such as DAMPs, which 
bind TLR4 on LECs within the graft parenchyma. (2) This leads to activation of NF-κB, and 
subsequent upregulation of expression of CCL21 and ICAM-1. (3) DCs migrate towards CCL21, 





The term lymphangiogenesis refers to the process of growth and expansion of lymphatic 
vessels from pre-existing vessels. This process is essential in development, as outlined 
above; however, in adults it is usually associated with pathological conditions. 
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Lymphangiogenesis has been implicated in cancer (141), chronic inflammation (142) and 
transplant rejection (143). Although it has been clear for many years that lymphatic 
networks expand within tissues of patients suffering these diseases, the mechanisms 
involved in the initiation and progression of lymphangiogenesis are only now starting to 
be deciphered, and targeted therapies towards them developed. This section will discuss 




1.2.8.1 Mechanisms of lymphangiogenesis 
The VEGF-C/D and VEGFR3 pathway is the central pathway in lymphangiogenesis 
(144). As mentioned previously, VEGFC/VEGFR3 signalling is essential for lymphatic 
sprouting from the cardinal vein in embryogenesis (145). Activation of VEGFR3 leads to 
phosphorylation of the serine kinases AKT and extracellular signal-related kinase (ERK), 
which promotes proliferation, migration and survival of LECs (146). PI3K, which is 
upstream of AKT, interacts directly with VEGFR3 and promotes tube formation (147). 
Interestingly, defects in the PI3K pathway affect lymphatic vasculature only and have no 
effect on blood vessels; suggesting that AKT functions distinctively in LECs. The 
congenital primary lymphedema condition Milroy’s disease is caused by missense 
mutations in the tyrosine kinase domain of VEGFR3 (105). 
 
The VEGF and VEGFR2 pathway plays less of a role in lymphangiogenesis than the 
VEGFC/VEGFR3 pathway. Specific activation of this pathway causes vessel 
enlargement but does not initiate sprouting (148), and deletion of the VEGFR2 gene in 
LECs does not affect lymphatic vessel function in embryogenesis and adult mice (149). 
There are also data to show that the Notch pathway plays a role in VEGF/VEGFR2-
induced lymphangiogenesis. It was found that lymphangiogenesis occurring via this 
pathway was enhanced when the Notch pathway was inhibited; and this was not seen in 




The collagen and calcium-binding EGF domain-containing protein 1 (CCBE1) is a highly 
conserved lymphagiogenic factor, and the result of deletion of this protein is similar to 
VEGFC deletion, with embryos not forming lymphatic vessels (151). Mutations in the 
CCBE1 gene in humans cause primary lymphedema in Henneken’s syndrome (152). 
Exogenous CCBE1 has little effect on inducing lymphangiogenesis, but seems to interact 
with the VEGFC pathway (153). 
 
Semaphorins and neuropilins have traditionally been described for their pivotal role in 
the central nervous system; however, they are now becoming recognised in the field of 
lymphangiogenesis. Neuropilin (NRP) 2 is a co-receptor for VEGFC and binding causes 
co-internalization of the two receptors which enhances VEGFC signalling (154). NRP2-
deficient mice have normal blood vasculature but decreased density of lymphatic 
capillaries in tissue (155). The NRP1 ligand semaphorin (SEMA) 3A is highly expressed 
in LECs and is particularly involved in lymphatic valve formation, where it has been 
shown to facilitate the migration of valve leaflet cells (156). 
 
Angiopoietin (ANG) 1 causes phosphorylation of the endothelial cell-specific tyrosine 
kinase receptor (TIE) 2 receptor in LECs which promotes sprouting (157), as does ANG2; 
however, the latter acts in an autocrine fashion (158). ANG2-deficient mice survive 
embryogenesis but after birth develop disease due to lymphatic hypoplasia (159). In 
pathological lymphangiogenesis, up-regulation of ANG2 promotes lymphangiogenesis 
associated with wound healing (160). 
 
Sphingosine 1-phosphate (S1P) is a bioactive phospholipid that has an essential role in 
vascular development and response to inflammation. It has been shown to induce LEC 
migration and tube formation in vitro (161). This molecule also stimulates ANG2 
production by LECs (162). When it is specifically deleted in LECs, the result is disruptive 




Many of the signalling pathways mentioned thus far function in a paracrine fashion with 
specific ligands being secreted by cells other than the LECs which make up the vessels, 
binding to receptors on the LEC and inducing signalling within the LEC. LECs themselves 
also communicate with each other via the Notch and ephrin B2 pathways. It is now 
becoming clear that Notch 1 is a regulator of lymphangiogenesis (150). As mentioned 
previously, inhibition of Notch 1 in vitro enhances lymphatic sprouting. Ephrin B2 mutant 
mice have miss-patterned lymphatic vasculature and lack lymphatic valves. In addition 
to its role in lymphatic development, ephrin B2 also functions in pathological 
lymphangiogenesis. It enhances VEGFR3 internalization following VEGFC stimulation, 
and blocking with specific antibodies has been shown to inhibit lymphangiogenesis in 
tumours (164). 
 
In terms of inhibiting lymphangiogenesis, there are two main endogenous inhibitors of 
the process. Firstly, transforming growth factor (TGF) β has been shown to inhibit 
lymphangiogenesis and the migration of LEC in vitro (165), and dampen 
lymphangiogenesis in in vivo wound repair models (166). Secondly, IFNɣ produced by T 
cells inhibits lymphangiogenesis in models of lymph node lymphatic expansion (167). 
 
Pro-lymphangiogenic signalling is active during embryogenesis to ensure correct 
development of the lymphatic system; it then reduces significantly but can be re-activated 
during disease. In cancer, expansion of lymphatics in the tumour environment enhances 
lymph node metastasis, and in chronic inflammation increased lymphatic density 
exacerbates the immune response. Because of this there has been a drive to develop 
anti-lymphangiogenic therapies, with some success in pre-clinical animal models (168). 
Most therapies have focused on inhibition of VEGFR3 signalling as the central 
lymphangiogenic pathway. This can be achieved by blocking the ligands from binding to 





The lymphangiogenic response in cancer and inflammation can also be inhibited 
indirectly by reducing the amount of VEGF-C in the diseased tissue. This is achieved 
mainly by reducing the influx of inflammatory cells into the tissue. Reducing pro-
inflammatory cytokine production can halt recruitment of VEGF-C-producing 
macrophages. Indeed, in a model of airway infection, anti-TNF-α antibodies were used 
successfully to decrease leukocyte infiltration and ensuing lymphatic remodelling (169). 
Systemic depletion of macrophages has also been shown to be successful in treating 
injury-induced lymphangiogenesis of the cornea (170).  
 
On the other hand pro-lymphangiogenic therapies are being developed for the treatment 
of lymphedema. VEGFC gene therapy has been used to restore lymphatic function in 
mouse models of lymphedema, and this has also been combined with lymph node 
transplantation to improve efficacy (171). 
 
There are many questions remaining in the field of pathological lymphangiogenesis, for 
instance: how are newly-formed lymphatic vessels maintained in diseased tissue and 
how long do they persist, and do anti- and pro-lymphangiogenic therapies have 
differential effects on lymphatic capillaries compared with collecting vessels? This is an 
emerging field with much promise but more pre-clinical research is required. 
 
 
1.2.8.2 Lymphangiogenesis in transplantation 
Despite the relative importance of the lymphatic vasculature in leukocyte trafficking and 
the allo-response, its pathophysiology in this setting has received little attention. It is now 
clear that extensive lymphatic remodelling, of which there are two types, occurs following 
solid organ transplantation (172). The first involves reconnection of donor lymphatics to 
those of the recipient, which has been demonstrated to occur within three weeks in an 
early model of renal transplantation (173). The dynamics of this process, however, have 
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yet to be investigated. The second mode of lymphatic remodelling in the allo-response 
which has received more attention (143, 172, 174), is the phenomenon of de novo 
lymphangiogenesis, whereby new lymphatic vessels are generated in response to the 
inflammatory milieu of the transplanted organ. Increased lymphatic density within the 
graft could lead to enhanced clearance of inflammatory infiltrate or increased trafficking 
of APCs to the local DLN to perpetuate the allo-response. Expansion of lymphatic 
networks in lymph nodes draining inflamed tissue has also been observed (175), and 
would suggest increased likelihood of interactions between APCs and T cells. It is also 
unclear whether de novo lymphangiogenesis in transplantation is a function of the 
disease process, or the system’s attempt to resolve it. The contribution of 
lymphangiogenesis and the lymphatic vasculature to the allo-response, and whether or 
not they impact positively or negatively on graft outcome, will be discussed in more detail 
later. 
 
Donor DC can trafﬁc to the spleen via reverse transmigration into the bloodstream, as 
shown for plasmacytoid DC after heart transplantation (88). Alternatively, DC may leave 
the donor organ via the open severed ends of the lymphatic vessels into the immediate 
surrounding area. They will then be taken up by the lymphatic capillaries in the local 
vicinity and trafﬁc to the local DLN. This latter process has been investigated in our 
laboratory, where single photo emission computed tomography/CT (SPECT/CT) imaging 
technology has been used to visualise and quantify post-transplant lymphatic flow in 
murine models of heterotopic heart transplantation (176, 177). In these models, lymph 
flows from the graft to the mediastinal lymph nodes, the DLN of the peritoneum, and this 
was further confirmed by the presence of donor-specific T cells in the lymph nodes 
highlighted by SPECT/CT. 
 
Lymphangiogenesis is frequently associated with transplant rejection (174, 178, 179), 
and the order of events leading to the appearance of new lymphatic vessels has been 
well characterised (174). The chief cellular constituent involved in the process of post-
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transplant lymphangiogenesis is the macrophage. LECs that make up the lymphatic 
vessels proliferate in response to pro-lymphangiogenic VEGF-C, produced by 
macrophages, binding to VEGFR-3 (146). CD11b+ macrophages were found to be critical 
for the development of inflammation-induced lymphangiogenesis in the cornea, and 
expressed the LEC markers LYVE-1 and Prox-1, and could form tube-like structures in 
vitro (180). Activation of the NF-κB pathway in LECs via the binding of endogenous 
ligands produced in reaction to tissue stress to TLRs, upregulates Prox-1 and VEGFR3 
expression which makes them more vulnerable to VEGF-C stimulation (181). 
 
As previously mentioned, during the transplant procedure the lymphatics vessels of the 
donor are not reconnected to those of the recipient, therefore it is likely that the efﬁciency 
of the lymphatic traffic of leukocytes in the initial post-transplant period, in terms of speed 
and number of cells transported, would be affected compared with intact lymphatic 
vessels. Expansion of the lymphatic networks within the graft and local DLN in response 
to inflammation is also likely to have an effect on graft outcome, either positively by 
promoting clearance of inflammatory infiltrate, or negatively by increasing DC migration 
to DLN and priming of recipient T cells. Research in this area is limited to a few studies, 
providing circumstantial evidence only and with conﬂicting results; some suggest a 
beneﬁcial role for lymphatics while others suggest the opposite, which will now be 
discussed.  
 
It has been shown that rejected human cardiac allografts have a lower density of 
VEGFR3+ lymphatics compared with patients with only moderate rejection (182). In an 
experimental model of canine lung transplantation, lack of lymphatic drainage was 
associated with rejected organs (183). Additionally, in rat cardiac allografts, a decrease 
in lymphatic density was observed in the inner myocardium post-transplantation (184). It 
is thought that the decrease in lymphatic density contributes to rejection through the 
retention of graft-destructive cells, and the accumulation of cytokines that perpetuate the 
local immune response. In support of this theory, it was shown that mechanical 
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interruption of lymphatic drainage induced the expression of multiple genes involved in 
acute inﬂammation, complement activation and B-cell humoral immunity (185). 
Lymphatic vessels in human kidney transplants are associated with lymphocytic 
inﬁltrates (172). Although the density of lymphatic vessels was not associated with acute 
or chronic rejection, grafts with lymphatic vessels within inﬁltrates had better graft 
function one year after transplantation compared to those without such vessels. Put 
together, these data provide circumstantial evidence that increased lymphatic vessel 
density within transplanted vascularised organs is associated with better graft outcome. 
This suggests that pharmacological modulation of lymphangiogenesis may be a possible 
strategy to improve graft outcome. 
 
Despite the evidence for a positive role for lymphatics in transplantation, it has been 
suggested that lymphatics may play the opposite role and impact graft survival 
negatively. Increased lymphatic drainage from donor organs may facilitate trafﬁcking of 
APCs to SLO, promoting allo-immunity. In our laboratory, using a mouse kidney model 
of transplant tolerance, the density of lymphatic vessels increased with time; however, 
their presence within the tertiary lymphoid organs that formed within the allografts was 
associated with reduced graft function (186). In a study of human renal transplant biopsy 
material, transplant rejection was observed to be caused by a lymphocyte-rich 
inﬂammatory inﬁltrate that attacked cortical tubules and endothelial cells. This 
corresponded with a >50-fold increase of lymphatic vessel density. Numerous CCR7+ 
cells within the inﬁltrates seemed to be attracted by CCL21 produced and released by 
LECs. The authors of this paper speculated that lymphatic neo-angiogenesis not only 
contributes to the export of the inﬁltrate, but is also involved in the maintenance of the 
allo-reactive immune response in renal allografts (143). It has also been demonstrated 
in islet allografts that interfering with lymphatic function leads to inhibition of 
lymphangiogenesis and prolonged or indeﬁnite allograft survival (178). It is not known 
whether an enhanced and more physiological connection between donor and recipient 
lymphatic vessels, through which DC can trafﬁc, may result in a stronger or weaker 
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immune response. Evidence to date for and against lymphatics being beneﬁcial in 
transplantation is sparse and mainly observational. Whether observed changes in 
lymphatic density are the cause or effect of the immune process is unknown. The effects 




1.3 The lymph nodes 
Presentation of antigens to T cells is central to the function of the adaptive immune 
system. This is mostly carried out by migratory DCs which transport antigen from the 
periphery to the SLO where naïve T cells reside. The SLO including spleen, lymph 
nodes, Peyer’s patches and tonsils are unique structures which provide the perfect 
conditions for immune surveillance of the periphery, ensuring close contact of the cells 
required to mount an effective immune response. Antigen arrives at these structures 
either passively through lymph draining from tissue, or actively through transport by 
migratory APCs. 
 
In this section the specific role of the lymph nodes in adaptive immunity will be explored; 




Lymph nodes are highly organised structures that develop at junctions of collecting 
lymphatics draining interstitial fluid and cells from tissues. Afferent lymphatics draining 
lymph from the periphery converge into the sub-capsular sinus of the lymph node. This 
is a sinus system lined with LECs interspersed with CD169+ macrophages, which 
functions to guide antigen and leukocytes towards the paracortex. The paracortex 
contains follicles rich in B cells and follicular DCs, ensuring capture and presentation of 
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soluble antigens. Deeper within the lymph node structure are the paracortical T cell 
zones, supported by reticular fibres and stromal networks for guidance of T cells and 
DCs. Lymph eventually enters the medullary sinuses, which converge to the efferent 
lymphatic vessel and leaves the lymph node (this process is reviewed in (187)). 
Leukocytes can also enter the lymph node from the blood system via blood vessels 
called high endothelial venules (HEVs); these are specialized for the delivery of naïve 
lymphocytes into the lymph node paracortex (188); (Figure 1.4). 
 
Dendritic cells which migrate to the lymph nodes from the periphery to present antigen 
to T cells eventually incorporate into the network of resident DCs, a process likely to be 
dependent on reduced signalling through CCR7 (189). By contrast, T cells that do not 
encounter cognate antigen in the lymph rapidly leave through the efferent lymphatics via 
cortical sinuses. Egress is dependent on S1P/S1PR1 signalling which over-rides the 




Figure 1.4- Structure of the lymph node.  
Leukocytes enter via the afferent lymphatic vessels and are guided towards the follicles which 
contain specialized DCs ensuring efficient delivery of antigen to naïve lymphocytes. They then 
enter the T cell zones within the paracortex. They leave via the medullary sinus which converges 





Development of the lymph nodes occurs during embryogenesis and is orchestrated by a 
subset of haematopoietic cells known as lymphoid tissue inducer cells (LTi). These cells 
interact with chemokine (c-x-c motif) ligand (CXCL) 13-producing mesenchymal cells, 
which give rise to lymph node stromal cells. It is thought that they are stimulated to 
produce CXCL13 by local production of retinoic acid by nerve fibres, although this is yet 
to be confirmed. CXCL13 attracts CXCR5-expressing LTi cells, and signalling via 
receptor activator of nuclear factor κB (RANK)-RANKL in these cells leads to 
upregulation of lymphotoxin (LT) α1β2. LTα1β2 causes mesenchymal cells to 
differentiate into lymphoid organiser cells (LTo) which leads to further recruitment of LTi 
cells resulting in a positive feedback loop for continued recruitment of lymph node 
progenitor cells. LTo cells then secrete CCL19 and CCL21, and express adhesion 
molecules to attract lymphocytes. These LTo cells eventually become the different 
stromal cell populations of the lymph node, i.e. fibroblastic reticular cells and follicular 
DCs (reviewed in (191)). 
 
 
1.3.3 Response to inflammation 
Lymph nodes draining inflamed tissue expand in size and cellularity through 
lymphangiogenesis. Remodelling of the lymph node expands the conduit systems 
delivering antigen and APCs from the inflamed tissue. This results in an increase in 
lymph flow towards the lymph node cortex. Increases in expression of leukocyte 
attracting chemokines such as CCL21 by HEVs and LECs attracts mature DCs from the 
inflamed tissue, and increases the likelihood of interactions with cognate T cells. The 
process of lymph node lymphangiogenesis in response to inflammation has been found 
to be dependent on B cells (192). Downregulation of S1P1, the receptor for sphingosine 






1.3.4 Lymphatic endothelial cells 
With the relatively recent discovery of specific markers for LECs in humans and mice 
such as LYVE-1 (134), podoplanin (193), and VEGFR3 (194); research in this field has 
grown. Pure populations of LEC can be isolated from a variety of tissue types and 
pathologies, allowing elucidation of their functionality, in particular their ability to regulate 
the adaptive immune response (reviewed in (122)). 
 
LECs express MHC class I and can present self-antigen to CD8+ T cells for tolerance 
induction in non-transplant models (195, 196). Lymph node LEC (LN-LEC) express high 
levels of the co-inhibitory molecule PDL1, and low levels of the classic co-stimulatory 
molecules CD80 and CD86. The absence of sufficient co-stimulatory signals leads to 
upregulation of PD1 on CD8+ T cells and subsequent engagement with PDL1 on LEC in 
the lymph node leading to CD8+ T cell deletion (196). Therefore, LECs contribute to 
peripheral tolerance by inducing CD8+ T cell deletion via PDL1. Lymph nodes have been 
found  to be an important site for self-tolerance induction, with many lymph node stromal 
cell types (including LEC) having the ability to directly present self-antigen and induce 
CD8+ T cell deletion (197). In a melanoma model, tumour expression of VEGF-C was 
found to promote immune tolerance of tumours by the host. Local tumour-specific CD8+ 
T cells were deleted, and LN-LECs were able to cross-present tumour antigen, and drive 
CD8+ T cell proliferation and apoptosis ex vivo (198). 
 
LEC-mediated induction of CD4+ T cell tolerance is less well characterised, although 
some progress has been made. It appears that CD4+ T cell self-tolerance induction is 
mediated by interaction with DCs. MHC class II expression by LECs is under the control 
of the IFN-γ inducible promoter IV, therefore its expression is minimal in steady-state 
conditions. Dubrot et al. found that LECs acquire antigenic peptide-MHC class II 
complexes from DCs as a result of cell-cell contact and exosomes (199). These acquired 
complexes are presented to cognate CD4+ T cells, resulting in CD4+ T cell dysfunction 
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and resistance to further stimulation. Others have found that LEC can act as antigen 
reservoirs for DCs (200). Although LECs do express MHC class II (albeit minimally), they 
cannot load endogenous peptides onto MHC II molecules due to the lack of H2-M. 
Therefore, they transfer endogenous peptides to DCs, which are then loaded onto MHC 
class II and presented to CD4+ T cells for tolerance induction. It appears that endogenous 
MHC class II expression by LECs functions to provide inhibitory signals to CD8+ T cells 
via interaction with the lymphocyte activation gene (LAG)-3 ligand (200). When human 
LN-LECs were stimulated with IFN-γ they were shown to take up and process antigen, 
but failed to stimulate proliferation of allogeneic CD4+ T cells (201). Indoleamine 2,3 
dioxygenase (IDO) was identified as a potential mediator of this inhibitory process, and 
the authors suggested a role for LEC in regulation of CD4+ responses in vivo. 
 
As well as effects on antigen presentation and T cell activation, LECs in the LN and 
periphery regulate T cell survival via production of IL-7. The role of IL-7 in the survival of 
naïve T cells is well documented (202, 203). Many cell types present within the LN 
produce IL-7, but LECs were found to be the dominant source (204); and IL-7-producing 
LECs have also been found in peripheral organs like the lungs and gut (205). 
Interestingly, IL-7 production by LECs might function in a negative feedback loop with T 
cells, with T cells having a negative impact on lymphangiogenesis (206), and LECs 
providing an essential cytokine (IL-7) for T cell survival. 
 
In addition to their impact on T-cell survival, LECs regulate trafficking of T cells within LN 
via S1P. LN-LECs were found to be the source of extracellular S1P which was essential 
for egress of activated T cells from lymph nodes (207). S1P acts via interaction with 
S1PR1 which is upregulated on T cells following activation (163). 
 
The information presented here provides evidence for the role of LECs in regulating the 
adaptive immune response. It is clear that LECs play a pivotal role in maintaining 
tolerance to self through providing inhibitory signals to activated CD8+ T cells. VEGF-C-
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activated LECs can also reverse anti-tumour immunity. Although LECs do not have a 
direct effect on CD4+ T cell immunity, as they are unable to present endogenous peptides 
in the context of MHC class II, they can regulate CD4+ T cell responses via interactions 




1.4 Outline of thesis 
The role that the lymphatic system plays in the immune response to a transplanted organ 
is complex and dependent on many different factors, including the type of organ graft 
and the degree of damage to the graft as a result of ischemic injury and immunological 
rejection. As outlined above, the lymphatic system acts not only as a passive conduit 
system for cell and molecular trafficking, but reacts to stimuli by modulating expression 
of cell surface and secreted molecules to ensure optimal interactions between immune 
cells in order to mount an effective immune response. The lymphatic system also 
displays a proliferative response under certain conditions.  
The aim of this thesis was to decipher the role of the lymphatic system in transplantation 
using mouse models of skin, heart and kidney transplantation. It was hypothesised that 
modulation of the lymphatic system of the donor and/or the recipient would prolong 
survival of allogeneic grafts as a result of reduced trafficking of donor passenger 
leukocytes between the graft and the recipient’s lymph nodes in the immediate post-
transplantation period. In addition to this it was hypothesised that the lymphatic 
endothelial cells of the lymph nodes draining a transplanted organ would undergo 
phenotypic changes as a result of the immune response.  
In chapter 3, anti-ICAM 1 antibody is used to block donor passenger leukocytes leaving 
donor grafts, in order to see if this promotes survival of allogeneic kidney grafts. In 
chapter 4 using a mouse with a conditional knockout of ephrin B2, lymphatics in donor 
organs are disrupted, to observe effects on graft survival. In chapter 5 the response of 
DLN LECs to transplantation has been studied, to determine whether they have the 










Phosphate-buffered saline (PBS) 
PBS tablets (Oxoid, Ltd., Basingstoke, UK) were dissolved in distilled water (1 tablet per 
100ml water). 
Periodate Lysine Phosphate (PLP) 
A lysine stock solution was made by adding 100ml of 0.2M lysine monohydrochloride 
(Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) to an equal volume of disodium 
hydrogen orthophosphate (Sigma-Aldrich; Merck KGaA). The pH was adjusted to 7.4 
and the solution stored at 4ºC. Immediately before use 1 volume of 4% 
paraformaldehyde was added to 3 volumes of lysine stock, and 214mg sodium 
metaperiodate (Sigma-Aldrich; Merck KGaA) was added per 100ml.  
Cell lysis buffer 
1g sodium hydroxide (NaOH); (Sigma-Aldrich; Merck KGaA) and 74.4mg ethylene-
diamine-tetra-acetic acid (EDTA); (Sigma-Aldrich; Merck KGaA) were dissolved in 
1000ml distilled water. 
Neutralization buffer 
6.5g TrisHCl (Sigma-Aldrich; Merck KGaA) was dissolved in 1000ml distilled water. 
Fluorescence activated cell sorting (FACS) buffer 
Consists of 2% fetal calf serum (FCS); (Sigma-Aldrich; Merck KGaA) in PBS. 
Red blood cell lysis buffer 
4.17g NH4Cl, 0.0185g EDTA and 0.5g NaHCO3 (all Sigma-Aldrich; Merck KGaA) were 
dissolved in 500ml de-ionised water. 
The solution was autoclaved, kept sterile and stored at 4ºC 
Lymphatic endothelial cell media 
Dulbecco’s modified eagle media (DMEM); (Thermo Fisher Scientific, Inc., Waltham, MA, 
USA) was supplemented with 2% FCS and 1.2mM CaCl2 (Sigma-Aldrich; Merck KGaA), 
and the required volume was filtered using a 0.45µm syringe filter. 
Heart digestion media 
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Roswell Park Memorial Institute medium (RPMI 1640) plus L-glutamine (Corning Inc, 
Corning, NY, USA) was supplemented with 10% FCS, 0.1mM β-mercaptoethanol 




BALB/c (H-2d) mice, purchased from Harlan UK Ltd. (Oxon, UK), were used as organ 
donors for kidney and heart transplantation, and recipients for skin, cardiac and renal 
transplantation. C57BL/6 (H-2b) mice, also purchased from Harlan, were used as 
recipients for cardiac transplantation. 
 
C57BL/6 mice expressing the enhanced yellow fluorescent protein targeted to the 
ROSA-26 locus (abbreviated to EYFP) in which EYFP is expressed ubiquitously (208) 
were bred in house and were used as recipients for renal transplantation. 
 
C57BL/6 mice with a spatially and temporally conditional knock-out for ephrin B2 
(abbreviated as ephrin B2-/-) were used as organ donors for skin, cardiac and renal 
transplantation. In these mice the CreERT2 recombinase is under the control of the Prox1 
promoter meaning that recombination of the floxed ephrin B2 gene only occurs in LECs. 
In addition, CreERT2 is an inducible Cre recombinase, and entry of the enzyme into the 
nucleus is dependent on the presence of tamoxifen. Adult ephrin B2-/- mice treated with 
tamoxifen lose expression of ephrin B2 in LECs within one week. Because ephrin B2 
plays an essential role in lymphatic valve maintenance, lymphatic vessels in these mice 
dilate and eventually disintegrate, causing death within two weeks (102). All ephrin B2-/- 
mice were used as organ donors eight days after tamoxifen treatment, before showing 
any obvious detrimental effects of the knock-out externally. However, upon dissection 
the effect of the knock-out is visible, as lymphatic vessels are dilated (Figure 2.1). Ephrin 





Figure 2.1- Photograph showing dilated lymphatic vessel in the abdomen of an ephrin B2-/- mouse 




Different combinations of genotype from the ephrin B2-/- colony were used for 
experiments: fully floxed (i.e. both ephrin B2 alleles floxed) and cre positive were used 
as experimental mice and are referred to as ephrin B2-/-, wild-type (i.e. neither ephrin B2 
alleles floxed) and cre positive were used as controls for some experiments, and fully 
floxed and cre negative were used as controls for other experiments. For maintenance 
of the ephrin B2-/- colony to ensure that all genotypes were available for experiments, 
two breeding pair combinations were used. Firstly for experimental ephrin B2-/- mice and 
wild-type controls, a heterozygous ephrin B2 (i.e. only one ephrin B2 allele floxed) cre 
positive male was bred with a heterozygous cre negative female. This combination gives 
six possible outcomes for offspring: homozygous cre positive, homozygous cre negative, 
heterozygous cre positive, heterozygous cre negative, wild-type cre positive or wild-type 
cre negative. And for maintenance of a line with no cre expression, a heterozygous cre 




All animals were kept in specific pathogen-free animal facilities, and used in accordance 
with the Animals (Scientific Procedures) Act 1986. Male mice between 8 and 12 weeks 




Ear samples were taken from ephrin B2-/- mice at weaning and genotyping performed to 
establish their cre and floxed ephrin B2 status. In addition, ear samples were taken from 
wild-type and ephrin B2-/- mice after tamoxifen treatment to confirm successful deletion 
of ephrin B2. 
 
DNA was extracted using the ‘hotshot’ method described by Truett et al. (209). Cell lysis 
buffer (75µl) was added to tubes containing ear sample, and heated to 95ºC for 30 
minutes with vortexing for 1 minute half way through incubation. Neutralization buffer 
(75µl) was then added to the tubes and they were stored at -20ºC. 
 
For PCR reactions, 2µl DNA was added into PCR tubes with: 12.5µl Taq PCR master-
mix (Qiagen, Inc., Valencia, CA, US), 2.5µl Coral load 10x (Qiagen, Inc.), 9.5µl DNAse 
free water (Qiagen, Inc.), and 0.5µl primer. The PCR conditions consisted of: an initial 
hold-step at 95ºC for 5 mins, followed by 35 cycles of; 95ºC for 30 seconds, 63ºC (50ºC 
for knockout genotyping) for 30 seconds and 72ºC for 30 seconds. PCR products were 
run on a 3% agarose gel.  
 
2.3.1 Primers 
Primer sequences were obtained from the original publication using these mice (102). 
Primers (Sigma-Aldrich; Merck KGaA) were initially diluted to 100µM in AE buffer 




Floxed ephrin B2: 
Forward (a): CTTCAGCAATATACACAGGATG 
Reverse (b): TGCTTGATTGAAACGAAGCCCGA 







2.3.2 DNA products 
Primers (a) and (b) yield a DNA product sized 380 base pairs (bp) when the sample is 
homozygous for the floxed ephrin B2 allele. If the sample is wild-type for the floxed allele 
(i.e. the gene is not floxed) the product is 262 bp. If the sample is heterozygous (i.e. one 
allele is floxed and one is not) the PCR yields two products, one 380 bp and one 262 bp. 
 
Primers (a) and (c) yield a DNA product sized 320 bp when the sample is homozygous 
floxed and tamoxifen-treated (i.e. when a homozygous cre positive mouse has been 




Figure 2.2- Schematic of floxed ephrin B2 showing location of primer sequence (a,b,c) binding.  
The ephrin B2 gene is flanked by two loxp sites which direct recombination by cre recombinase. 
When genotyping PCR is performed with primers a and b a DNA product of 380 bp is made. 
When genotyping PCR is performed with primers a and c on homozygous floxed mice after 




2.4 Animal models of transplantation 
For all transplantation procedures, donor and recipient mice were anaesthetised with 
isoflurane (Merial animal health, Ltd., Essex, UK), and recipient mice received 0.1mg/kg 
buprenorphine hydrochloride as analgesic (Vetergesic) (Alstoed, Ltd., Melton Mowbray, 
UK) subcutaneously prior to surgery.  
 
2.4.1 Technical success 
Due to the technical challenges involved in mouse heart and kidney transplantation 
models it is important to note that not all procedures are successful. In the hands of both 
operators ~95% of heart transplant procedures are successful, and this can be 
demonstrated by perfusion of the heart after removal of clamps and initiation of heart 
beat in the transplanted organ. Similarly, success in kidney transplantation is also 
dependant on perfusion of the donor organ after removal of the clamps. This is easily 
determined by a change in colour of the kidney from pale to dark pink/red. In the hands 
of both operators ~70% of kidney transplant procedures are successful. 
For results presented in this thesis, more than one person was involved in the 
transplantation procedures. In order to limit variability in data as a result of inter-
operational variation in technical success, for experiments involving two operators such 
as that presented in section 3.2, both operators were responsible for transplanting a 
similar number of mice in both the experimental and control group. In all other 
experiments where more than one operator was to carry out procedures they were 





A splenectomy was performed before transplantation in some recipients in order for the 
impact of DPL trafficking via lymphatics on graft outcome to be studied in isolation. In 
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addition to the lymphatic route, DPL exit the graft via blood vessels and traffic to the 
spleen where they encounter allo-specific T cells (52).  
 
For skin graft recipients, splenectomy was performed seven days before skin 
transplantation. An incision was made on the ventral left side of the mouse, and a small 
portion of the bowel retracted upwards to allow visualisation of the spleen. The vessels 
supplying the spleen were ligated with 7/0 silk suture (Pearsalls, Ltd., Taunton, UK), and 
cut close to the spleen. The spleen was removed and the incision closed with 4/0 suture 
(Unik Surgical Sutures, Taipei, Taiwan). For heart and kidney transplant recipients 
splenectomy was performed at the time of transplantation. 
 
 
2.4.3 Skin transplantation 
Skin transplantation was performed as described by Billingham et al. (210). A section of 
tail skin was removed from the donor, trimmed to an approximate size of 1cm2, and 
placed on saline-soaked gauze on ice whilst the recipient was prepared. A small section 
of skin, similar to the size of the graft, was removed from the dorsal aspect of the 
recipient. For double skin transplant recipients two sections of skin were removed, one 
on either side of the spine. The donor skin(s) was placed in the opening, and fixed in 
place with Germolene new skin (Bayer, Newbury, UK). The skin was covered with a 
paraffin-coated mesh dressing (Johnson and Johnson, New Brunswick, NJ, USA), dry 
gauze was placed on top and the animal was wrapped in Transpore tape (3M, 
Maplewood, MN, USA). The bandages were removed after seven days, and rejection of 
the graft monitored by observation. The graft was considered rejected when it was more 





2.4.4 Heart transplantation 
Cardiac transplantation was performed as first described by Corry et al. (211). A large v-
shaped incision was made in the donor, and the gut was removed to reveal the inferior 
vena cava (IVC) and the aorta. Heparinized saline (500µl; 200units/ml); (Leo Pharma, 
Hurley, UK) was injected into the IVC and allowed to circulate for 1 minute, then the aorta 
was cut to allow exsanguination of the animal. The rib cage was opened to reveal the 
heart; and the IVC, azygous veins and the superior vena cava were tied with 7/0 silk 
suture (Pearsalls, Ltd.) and cut. The aorta and the pulmonary artery were cut straight 
across using microscissors (Fine Science Tools, Heidelberg, Germany). A tie was then 
placed around the entire heart and it was removed from the animal and placed in sterile 
saline on ice whilst the recipient was prepared.  
 
The anaesthetized recipient was shaved, the abdomen swabbed with povodine iodine, 
as Vetasept (Animalcare, York, UK), and a sterile drape placed over the operating area. 
A midline incision was made, and the bowels and bladder retracted and covered in 
saline-soaked sterile gauze. The IVC and aorta were exposed, and the lumbar veins 
which drain into the IVC were tied with 7/0 silk suture. Microvessel clamps (Fine Science 
Tools) were placed at the top and bottom of the IVC and aorta. A venotomy and 
aortotomy were made using a 21 gauge needle (Terumo UK Ltd., Bagshot, UK), and 
extended with microscissors. Anchor stitches were placed at the top and bottom of the 
donor and recipients aorta, and the left-hand walls were anastomosed with a running 
stitch using 10/0 nylon suture (Unik Surgical Sutures). This was tied to the top anchor 
stitch; then the heart was flipped over to complete anastomosis of the right-hand wall. 
The pulmonary artery was anastomosed to the recipient IVC in the same way, except 
that the right wall was completed first. A small piece of Spongostan (Ferrosan Medical 
Devices, Soborg, Denmark) was placed over the anastomoses before removal of the 




Cardiac grafts were monitored by palpation of the abdomen, and the strength of beating 
assessed according to the scale developed by Superina et al. (212). Rejection was 
defined as absence of a palpable heartbeat on 2 consecutive days. 
 
 
2.4.5 Kidney transplantation 
Renal transplantation was performed as described by Han et al. (213). A v-shaped 
incision was made in the donor and the gut removed to reveal the left kidney. The 
gonadal and adrenal veins, which branch off the renal vein were tied twice with 7/0 silk 
suture and cut between the ties. A loose tie was placed on the aorta above the junction 
with the renal artery, and the ureter was cut close to the bladder. Heparinised saline 
(200µl; 200units/ml) was injected into the IVC and allowed to circulate for 1 minute. The 
tie on the aorta was tightened, and the needle was removed to allow exsanguination of 
the animal. The renal vein was cut at its junction with the IVC, and the aorta was cut 
obliquely below the renal artery and above the tie made earlier. The kidney was removed 
and kept in sterile saline on ice whilst the recipient was prepared. 
 
The anaesthetized recipient was shaved, the abdomen swabbed with povodine iodine, 
and a sterile drape placed over the operating area. A midline incision was made, and the 
bowels and bladder retracted and covered in saline-soaked sterile gauze. A tie was 
placed around the left renal vein and artery, and the left kidney removed. The IVC and 
aorta were exposed, and the lumbar veins which drain into the IVC were tied with 7/0 silk 
suture. Microvessel clamps were placed at the top and bottom of the IVC and aorta. A 
venotomy and aortotomy were made using a 21 gauge needle, and extended with 
microscissors. Anchor stitches were placed at the top and bottom of the donor and 
recipients aorta, and the left-hand walls were anastomosed with a running stitch using 
10/0 nylon suture. This was tied to the top anchor stitch, then the kidney was flipped over 
to complete anastomosis of the right-hand wall. The renal vein was anastomosed to the 
IVC in the same manner except that the left-hand wall was stitched from inside the lumen. 
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A small piece of Spongostan was placed over the anastomoses before removal of the 
clamps. The midline incision was closed with a 4/0 suture. 
 
Seven days following transplantation, the right native kidney was removed. From this 
point the renal graft became life-sustaining and renal function was monitored weekly by 
measuring blood urea nitrogen (BUN). Rejection was defined as death of the recipient 
due to kidney failure or the requirement for it to be culled due to uraemia, as defined by 
BUN of >30 mmol/L, causing ill health. 
 
 
2.5 Blood urea nitrogen measurement (BUN) 
BUN was used as a measure of kidney function in kidney transplant recipients. Blood 
was taken from the tail vein of mice, and centrifuged at 1300RPM for 30 minutes. The 
serum was removed by pipetting and stored at -20ºC. For analysis, 5µl of serum was 
added to 500µl Infinity Urea (Clindia Benelux B.V, Leusden, The Netherlands), and the 
absorbance at 340nm read on a spectrophotometer (Beckman Coulter (UK), Ltd., High 
Wycombe, UK). BUN was then calculated according to the manufacturer’s instructions.  
 
 
2.6 Monoclonal antibody therapy 
A number of EYFP recipients of BALB/c kidney grafts were treated with a rat anti-mouse 
ICAM-1 blocking antibody (IgG2b isotype); (Bioxcell, West Lebanon, NH, USA). The 
antibody was administered to kidney transplant recipients intravenously (IV) via the tail 





2.7 Tamoxifen treatment 
Ephrin B2-/- mice to be used as organ donors were injected intraperitoneally (IP) with 5µg 
tamoxifen (Sigma-Aldrich; Merck KGaA) dissolved in corn oil (Sigma-Aldrich; Merck 
KGaA) eight days prior to transplantation. 
 
 
2.8 Tissue harvesting 
2.8.1 Mediastinal lymph nodes 
Following heterotopic heart transplantation into the abdomen of a mouse (as described 
above), lymph flows from the organ into the peritoneal cavity and enters the 




Figure 2.3- Location of the mediastinal lymph nodes in the mouse. 
Numbers and exact positions of these lymph nodes vary slightly between individual mice, but 
normally consist of: the right anterior superior (RAS) and right anterior inferior (RAI) mediastinal 
lymph nodes, located on top of the right brachiocephalic vein; the right posterior (RP) mediastinal 
lymph node, located underneath the right brachiocephalic vein; and the left superior (LS) and left 





This has been demonstrated by our group in published experiments (176). These lymph 
nodes can be visualised following IP administration of 0.5% Evans Blue (Sigma-Aldrich; 
Merck KGaA) (Figure 2.4). 
 
 
Figure 2.4- Location of mediastinal lymph nodes.  
Photograph of the chest cavity of a mouse following intraperitoneal injection of Evans Blue, 





Skin, hearts and kidneys were harvested in PLP. PLP-fixed tissue was kept at 4ºC for 4 
hours, then transferred to a 13% sucrose solution overnight at 4ºC. Tissue was 
embedded in OCT (Thermo Fisher Scientific, Inc.), gradually cooled on dry ice, and 
stored at -80ºC. Sections (5µm) were cut using a cryostat (Bright, Luton, UK), air dried 
overnight, and fixed in ice cold acetone for 5 minutes. Endogenous peroxidase activity 
within the tissue was quenched with 3% H2O2 in PBS (Oxoid Ltd.), and avidin/biotin was 
blocked using a kit (Vector Laboratories, Peterborough, UK) according to manufacturer's 
instructions. Tissue was incubated with anti-lymphatic vessel endothelial hyaluronan 
receptor 1 (LYVE-1) polyclonal antibody (Abcam, Cambridge, UK) at a 1:500 dilution with 
PBS containing 5% bovine serum albumin (Sigma-Aldrich; Merck KGaA), overnight at 
4ºC. After washing with PBS, a biotin conjugated anti-rabbit secondary (Biolegend, San 
Diego, CA, USA) at a 1:100 dilution was added for 30 minutes at room temperature. This 
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was followed by incubation with Streptavidin horseradish peroxidase solution (BD 
Biosciences, Franklin Lakes, NJ, USA) for 30 minutes at room temperature. LYVE-1 
staining was detected using a Novared detection kit (Vector Laboratories) according to 
manufacturer’s instructions. For counter-staining of nuclei, sections were incubated in 
Mayer’s haematoxylin (VWR, Lutterworth, UK) for 3 minutes, followed by washing in 
running tap water for 10 minutes. Sections were then dehydrated through dips in 90% 
followed by 100% ethanol and xylene. Slides were mounted in DPX (VWR). LYVE-1 
staining was quantified using ImageJ software. 
 
For intracellular Foxp3 staining in PLP fixed kidney sections, the same protocol was 
followed, except slides were incubated with anti-Foxp3 antibody (Biolegend) at a 1:400 




Renal grafts were harvested in 10% formalin. Formalin fixed tissue was processed using 
a Leica ASP200 tissue processor; and embedded in wax. Sections (4µm) were cut using 
a microtome (Leica, Wetzlar, Germany), and baked overnight at 60ºC. Periodic acid 
Schiff’s staining (PAS) was performed by removing wax in xylene and rehydration 
through dips in 100% followed by 90% ethanol, and washing in running tap water for 5 
minutes. Sections were incubated in 1% periodic acid for 10 minutes followed by washing 
with distilled water. Sections were then incubated in Schiff’s reagent (VWR) for 10 
minutes followed by washing in running tap water for 5 minutes. Sections were then 
incubated in Mayer’s haematoxylin (VWR) for 3 minutes, followed by washing in running 
tap water for 10 minutes. Sections were then dehydrated through dips in 90% followed 





2.9 Real-time PCR 
In order to quantify the amount of DPL that had trafficked from the graft to the DLN of 
the recipient, a real-time PCR assay for a donor-specific gene was used. To calculate 
the copy number of the donor-specific gene from unknown samples, a mean was 
calculated from triplicate ct values, applied to a standard curve generated from donor 
strain DNA, and corrected for the total amount of DNA in the sample. 
 
 
2.9.1 Genomic DNA extraction 
Mediastinal lymph nodes were harvested from cardiac and renal transplant recipients 
and stored at -20˚C. DNA was extracted using the DNeasy mini kit from Qiagen, Inc., 
according to the manufacturer’s protocol. The quantity of total DNA within samples was 




2.9.2 zfy1 PCR 
A PCR assay for zfy1 was used to quantify donor DNA in recipient DLN of mice receiving 
male BALB/c kidney grafts. Zfy1 encodes a zinc finger protein located in the testes 
determining region of the Y chromosome (214), and is therefore in this case a donor-
specific gene as only male mice were used as donors. This assay has previously been 
used by our laboratory to quantify DPL in a heart transplantation model (177). 
 
PCR reactions were made up to a final volume of 20µl in white hard-shell 96-well PCR 
plates. The PCR reaction was set up as previously described (215). Data was analysed 





2.9.3 cre PCR 
A PCR assay for cre was used to quantify donor DNA in recipient DLN of mice receiving 
either wild-type or ephrin B2-/- heart grafts; as the donor mice had been transduced with 
the cre gene, and therefore DPL within the grafts contained a copy of the gene.  
 
PCR reactions were made up to a final volume of 20µl in white hard-shell 96-well PCR 
plates (Bio-Rad Laboratories, Inc., Hercules, CA, USA). PCR reactions consisted of: 10µl 
Taqman (Invitrogen; Thermo Fisher Scientific, Inc.), 1µl primer mix (assay Mr00635245, 
FAM conjugated probe); (Applied Biosystems; Thermo Fisher Scientific, Inc.), and 
genomic DNA (extracted from DLN as above) diluted to a volume of 9µl in DNase free 
water (Qiagen, Inc.). After addition of reaction mixtures to wells of the plate, the plate 
was spun for 1 minute at 1500RPM. The PCR conditions were as follows: an initial hold 
step of 50ºC, then heating to 95ºC, and 40 cycles of 15 seconds at 95ºC followed by 
annealing for 1 minute at 60ºC. Data was analysed using the Bio-Rad CFX software. 
 
2.9.4 Calculation of cell number  
The CFX software calculates the amount of target DNA (i.e. zfy1 or cre) in samples by 
comparing ct values to a standard curve. As the copy number of the cre transgene in 
donor mice was unknown, individual standard curves using DNA from each donor mouse 
were run at the same time as the recipient DLN DNA samples. For the zfy1 assay this 
was not necessary as all male donor mice have one copy of the gene per cell (214).  
In order to calculate the number of donor cells within recipient DLN DNA samples from 
the PCR assays the c value was used. The c value denotes the size of an organism’s 
genome in terms of the mass of DNA (in picograms) in a haploid cell, i.e. a gamete, or 
half the amount of DNA in a diploid cell. The c-value for mus musculus is 2.45 (216). 
 Therefore, the number of donor cells was determined by calculating the percentage of 
the total sample DNA which was donor specific (i.e. the proportion value), converting this 





2.10 Tissue digestion for flow cytometry 
2.10.1 Heart 
Mice were anaesthetised with isoflurane, and exsanguination was achieved by drawing 
blood from the abdominal IVC. The rib cage was then opened to reveal the heart. The 
heart was perfused with 1ml cold sterile saline through the aorta and removed from the 
animal. The heart was placed in a 40mm petri dish and sliced in half using a blade. Any 
remaining blood was flushed from the ventricles using saline, and the tissue placed in a 
fresh petri dish containing 1ml heart digestion media. The tissue was minced to 1mm 
pieces using microscissors and transferred to a 5ml polypropylene tube, which was 
placed on ice. 
 
Tissue was allowed to settle at the bottom of the tube and supernatant aspirated to a 
50ml Falcon tube with 100µm nylon mesh attached. The mesh was washed with heart 
digestion media, and the tube placed on ice. To the heart tissue, 1ml digestion mix (heart 
digestion media plus 10µg/ml type 1 collagenase (Sigma-Aldrich; Merck KGaA) and 
10µg/ml DNAse 1) pre-warmed to 37ºC was added, and the tube incubated at 37ºC for 
15 minutes. The tube was vortexed for 1 minute half way through the incubation.  
 
This process was repeated, and after the final incubation the remaining undigested tissue 
was mashed through a 100µm nylon mesh with the plunger of a 1ml syringe. The tube 
containing the digested heart tissue was centrifuged at 1100RPM for 5 minutes at 4ºC. 
The supernatant was discarded and the tissue re-suspended in 3ml 0.01M EDTA in FCS 
at room temperature. The suspension was then layered over 3ml Histopaque-1077 
(Sigma-Aldrich; Merck KGaA) at room temperature, and centrifuged for 30 minutes at 




Leukocytes form an opaque layer between the Histopaque-1077 and the FCS. Due to 
low yields of leukocytes from heart tissue, the FCS and leukocyte layer were carefully 
removed to a 15ml Falcon tube and topped up to 10ml with PBS. The tube was spun at 
1100RPM for 10 minutes at 4ºC. The supernatant was discarded and the heart 




Mice were anaesthetised with isoflurane, and exsanguination was achieved by drawing 
blood from the abdominal IVC. The kidney was removed and placed in heart digestion 




2.10.3 Lymph nodes 
Stromal cells were isolated from mediastinal lymph nodes of mice receiving heart grafts 
using a technique described by Broggi et al. (218) with some modifications. Lymph nodes 
were harvested into a 40mm petri dish containing 1ml LEC digestion media, and the 
capsules disrupted using a 27G needle attached to a 1ml syringe. The tissue was then 
transferred to a 5ml polypropylene round-bottomed tube, and washed with a further 1ml 
LEC digestion media to ensure all tissue was transferred. The tubes containing lymph 
node tissue were kept on ice for transportation between the biological services unit and 
laboratory. 
 
Tissue was allowed to settle at the bottom of the tube and the supernatant was aspirated 
using a sterile pastette to a sterile 50ml Falcon tube with 100µm nylon mesh attached. 
The mesh was washed with LEC digestion media, and the tube placed on ice. To the 
lymph node tissue, 750µl digestion mix 1 (LEC digestion media plus 1mg/ml collagenase 
IV (Worthington Biochemical Corporation, Lakewood, NJ, US) and 40µg/ml DNAse 1 
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(Roche Diagnositcs, Basel, Switzerland)) pre-warmed to 37ºC was added, and the tube 
incubated at 37ºC for 30 minutes with 30 seconds gentle vortexing every 10 minutes.  
 
Tissue was again allowed to settle at the bottom of the tube and supernatant aspirated 
to the 50ml Falcon tube with 100µm nylon mesh attached. The mesh was washed with 
LEC digestion media, and the tube placed on ice. To the lymph node tissue, 750µl 
digestion mix 2 (LEC digestion media plus 3.5mg/ml collagenase D (Roche Diagnositcs) 
and 40µg/ml DNAse 1) pre-warmed to 37ºC was added, and the tube incubated at 37ºC 
for 10 minutes. 
 
The tissue was further disaggregated by pipetting up and down using a 1000µl pipette 
set at 700µl for approximately 2 minutes or until no visible tissue fragments remained. 
The digested tissue was then transferred to the 50ml Falcon with 100µm mesh attached. 
The mesh was washed 5 times with 1ml LEC digestion media, and the tube placed on 
ice. 
 
The tube containing digested lymph node tissue was centrifuged at 1500RPM for 5 
minutes at 4ºC. The supernatant was discarded and the lymph node cells were re-











2.11 Flow cytometry 
 
Table 2- Table showing antibodies used for flow cytometry. All antibodies were supplied by 
Biolegend. 
 
Target Clone Function Fluorochrome Dilution 
     
CD45 30-F11 Leukocyte common 
antigen 
Alexa Fluor 700 1:100 
     
Podoplanin 8.1.1 Lymphatic endothelial cell 
marker 
PE 1:200 
     
CD3 I7A2 T cell marker APC 1:100 
     
CD4 GK1.5 T cell marker (helper) PE 1:100 
     
CD8 53-6.7 T cell marker (cytotoxic) FITC 1:100 
     
CD44 IM7 T cell activation maker PE-Cy7 1:100 
     
CD31 MEC13.
3 
Lymphatic endothelial cell 
marker 
APC 1:200 
     
PDL1 10F.9G2 Co-inhibitory molecule PE/Cy7 1:100 
     
I-Ab AF6-
120.1 
MHC class II molecule 






     
CD11c N418 Dendritic cell marker FITC 1:100 
     
CD11b M1/70 Macrophage marker APC-Cy7 1:100 
     
Dead cells Sytox 
blue 
Nucleic acid stain BV405 1:1000 
     






2.11.1 Lymphatic endothelial cells 
One million cells were added to each tube for staining.  FACS buffer (1ml) was added 
and the tubes centrifuged at 1100RPM for 5 minutes at 4ºC. The supernatant was 
discarded and the cells re-suspended in 100µl FACS buffer. Fluorochrome-conjugated 
antibodies specific for LEC markers and co-inhibitory/co-stimulatory molecules were 
added according to the dilutions in Table 2 and the tubes incubated in the dark on ice for 
30 minutes. 
 
The stained cells were washed in FACS buffer as before to remove unbound antibodies. 
The supernatant was discarded and the stained cells re-suspended in 500µl Sytox blue 
dead cell stain (Thermo Fisher Scientific, Inc.). Cells were analysed on a Fortessa flow 
cytometer (BD Biosciences). 
 
 
2.11.2 Kidney and heart leukocytes 
For heart leukocytes the total amount of recovered leukocytes from each heart was 
added to a 5ml polypropylene tube. For kidney leukocytes one million cells were added. 
FACS buffer (1ml) was added and the tubes were centrifuged at 1100RPM for 5 minutes 
at 4ºC. The supernatant was discarded and the cells re-suspended in 100µl Fc block (BD 
Biosciences) diluted in FACS buffer. The tubes were incubated for 20 minutes in the dark 
on ice. Fluorochrome-conjugated antibodies specific for DC markers and co-stimulatory 
molecules were added according to the dilutions in Table 2, and the tubes incubated in 
the dark on ice for 30 minutes. 
 
The stained cells were washed in FACS buffer as before to remove unbound antibodies. 
The supernatant was discarded and the stained cells re-suspended in 1ml Sytox blue 






Naïve splenocytes from the same strain were used as a control for leukocyte markers in 
flow cytometry experiments. Splenocytes were isolated by; disaggregation of tissue 
through a 70µm sieve attached to a 50ml Falcon tube, followed by washing in PBS. Red 
blood cells were lysed by addition of 5ml RBC lysis buffer and incubation on ice in the 
dark for 10 minutes. Cells were washed in PBS, re-suspended in FACS buffer, and 
stained according to the protocol for the experimental sample. 
 
 
2.11.4 Analysis of flow cytometry data 
All flow cytometry analysis was carried out using Flowjo software (Tree Star, Inc., 
Ashland, OR, USA). Absolute numbers of specific cell types were calculated using the 
proportion value of the appropriate gate and multiplying this by the total amount of cells 
counted at the end of the digestion protocol. This was then expressed in terms of the 
weight of the tissue (whenever possible). For all samples in a particular experiment the 
same number of cells were added to the tube for staining. In addition the same number 




All data was analysed using Graphpad Prism software (Graphpad Software Inc., La Jolla, 
CA, USA). Un-paired t tests with two-tailed p values were used for all data. Data are 
expressed as mean values with error bars representing standard error of the mean. For 






Chapter 3 Using anti-ICAM-1 antibody therapy to block post-





The immune response to an allograft is initiated when donor-derived allo-antigens are 
recognised by the host immune system, leading to the priming of graft-destructive T cells. 
This can occur via three distinct pathways: the direct, indirect and semi-direct. Each 
relies on efficient trafficking of donor and recipient immune cells between the graft and 
SLO, i.e. the local DLN and spleen, via lymph and blood, respectively. SLO provide the 
perfect niche for interactions between APCs and allo-specific T cells and thus are crucial 
for an effective immune response (90, 91), as both DPL and host allo-reactive T cells are 
present in low numbers. Such niches provide a physical locality to facilitate effective 
interactions between them. 
 
During the transplantation procedure the donor lymphatic vessels are not reconnected 
to the recipient lymphatics because of their small size. Therefore, they are left open-
ended in the initial post-transplantation period. They do eventually reconnect to the 
recipient lymphatic vasculature (173); however, studies in this field are limited and the 
timing and dynamics of the process still remain largely unknown. Our laboratory has 
previously used SPECT/CT to demonstrate leakage of lymph from the donor organ and 
tracked the pathway of flow. Following injection of the radioactive tracer Nanocoll, which 
is used to visualise lymphatic flow in humans, into the heart graft; full body imaging 
allowed visualisation of the pattern of lymphatic flow from the graft. Results from this 
study demonstrated that in the murine heterotopic heart transplant model, where the 
donor heart is placed in the peritoneal cavity, lymph that leaks from the severed ends of 
donor lymphatics enters the peritoneal cavity and is picked up by the diaphragmatic 
lymphatics which drain into the mediastinal lymph nodes. Allo-specific CD8+ T cells were 
found in the mediastinal lymph nodes after transplantation, which further confirms these 
lymph nodes as the destination of DPL which have left the graft via the severed 
lymphatics. This route of lymph flow is maintained even after connection of donor 
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lymphatics with those of the recipient, which happens several weeks after transplantation 
(176). 
 
It has been demonstrated in vitro that in response to inflammatory cytokines (in particular 
TNFα), LECs upregulate expression of key adhesion molecules (ICAM-1, vascular cell 
adhesion protein (VCAM) -1 and E-selectin) and secrete specific chemokines which 
enable transmigration of DC across the lymphatic endothelium (129, 130). The authors 
of these papers also used monoclonal antibodies in vivo to demonstrate reduced 
mobilization of DC to the DLN when this pathway is blocked. Chemokine gradients 
produced by the lymphatic vessel also guide DC towards the DLN (219). Interactions 
between donor-derived APCs and recipient T cells within the lymph node principally 
contribute to the induction of allo-immunity via the direct pathway of allo-recognition. This 
relies on efficient trafficking of DPL from the graft to the DLN via afferent lymphatic 
vessels. 
 
It was hypothesised that blockade of the ICAM-1 pathway would hinder trafficking of DPL 
into recipient lymph nodes and, therefore prolong graft survival. Anti-ICAM-1 antibody 
therapy is known to have a beneficial effect on allograft survival, and has been used to 
demonstrate the importance of co-stimulation blockade in tolerance induction (220, 221). 
Anti-ICAM-1 in conjunction with anti-LFA1 can prolong survival of mouse cardiac 
allografts, but it was used in the context of blocking T cell infiltration into the grafts (222, 
223). Its effect on migration of DPL out of the graft has not been studied. Here, an anti-
ICAM-1 antibody was used in a mouse kidney allograft model, to assess the contribution 
to the allo-response of immediate post-transplantation trafficking of DPL via the 
lymphatic route to recipient lymph, where the spleen of the recipient is removed to 





3.2 Quantification of DPL trafficking using real-time PCR 
To determine the effect of ICAM-1 blockade on DPL trafficking, female EYFP (H-2b) 
recipients of male BALB/c (H-2d) kidney grafts were treated with either anti-ICAM-1 
antibody or vehicle control (saline) 30 minutes before transplantation surgery, and also 
received a splenectomy at the time of transplantation (Figure 3.1). EYFP recipients were 
used here because they had been used in a previous study by our laboratory that 
assessed post-transplantation lymphatic flow (177). A dose of 200µg per mouse was 
chosen after examination of the literature. Studies by others on the effect of anti-ICAM-
1 antibody therapy on allograft survival used doses of antibody between 100 and 200µg 
per mouse (224-226). The proportion and absolute number of donor cells in the 
mediastinal lymph nodes 24 hours post-transplantation was determined by real-time 
PCR for the donor-specific male gene zfy1. The time point of 24 hours after 
transplantation was chosen as the time to quantify DPL in recipient DLN after 
examination of the literature as the study by Benichou and colleagues showed that DPL 
were undetectable in heart transplant recipient DLN past day 1 (58). It is also known that 










Quantitative real-time PCR was used to quantify donor cells in recipient lymph nodes 
because of its sensitivity and accuracy. The genomic target to be amplified was the male-
specific gene, zfy1, which is located on the Y chromosome, and thus only male (donor) 
DNA would be amplified. A standard curve was generated with DNA isolated from male 
BALB/c mediastinal lymph nodes (Figure 3.2) and the proportion of male DNA in 
transplant recipient DLN was quantified from the standard curve. This data could then 
be converted to the number of cells of donor origin in the recipient sample by using the 
c-value which refers to the total amount of DNA in each diploid cell of the organism (227).  
 
 
Figure 3.2- Real-time PCR standard curve for zfy1 using male BALB/c genomic DNA.  
The ct value formed a linear relationship with the amount of male DNA in the reaction (R2=0.9654), 
allowing for reliable quantification of male DNA within experimental samples. Ct value refers to 
the PCR cycle number where the fluorescent signal rises above background. 
 
 
The proportion of donor-derived DNA within recipient DLN 24 hours after transplantation 
was significantly reduced in anti-ICAM-1 antibody-treated recipients compared with 
vehicle controls (0.03±0.01% vs. 0.07±0.02%, p=0.0375); (Figure 3.3). When the data 
for donor-derived DNA as a proportion of the total DNA was converted to values 
corresponding to the number of donor-derived cells within recipient lymph nodes 
(according to the calculations described in section 2.9.4) there was no significant 





Figure 3.3- Quantification of donor DNA within recipient DLN 24 hours post-transplantation. 
Male BALB/c kidneys were transplanted into female EYFP recipients and 24 hours later the 
mediastinal lymph nodes were harvested, subjected to DNA extraction and analysed using a real-
time quantitative PCR assay for a the donor specific gene, zfy1. The proportion of the total amount 
of recipient draining lymph node DNA that was of donor origin was calculated by comparing ct 
values to the standard curve in Figure 3.2. The proportion of recipient DLN DNA that was donor-
derived 24 hours post-transplantation was reduced in anti-ICAM-1 antibody-treated recipients 
compared with vehicle control-treated recipients, p=0.0375.  Each data point represents the 






Figure 3.4- Quantification of donor cells within recipient DLN 24 hours post-transplantation. 
Male BALB/c kidneys were transplanted into female EYFP recipients and 24 hours later the 
mediastinal lymph nodes were harvested, subjected to DNA extraction and analysed using a real-
time quantitative PCR assay for a the donor specific gene, zfy1. The proportion of the total amount 
of recipient draining lymph node DNA that was of donor origin was calculated by comparing ct 
values to the standard curve in Figure 3.2. The number of donor-derived cells was calculated 
using the c-value which corresponds to the total amount of DNA per cell. There was no difference 
in the number of donor-derived cells in recipient DLN between anti-ICAM-1 antibody-treated and 
vehicle control-treated recipients, p=0.2787. Each data point represents the average of triplicate 





3.3 Survival of allogeneic kidney graft in anti-ICAM-1 antibody-treated 
recipients 
Rejection of allografts depends on presentation of donor antigen to recipient T cells, and 
recipient lymph nodes provide the perfect niche for this interaction. Therefore, having 
demonstrated that treatment with anti-ICAM-1 antibody before transplantation led to a 
reduction in donor cell trafficking from the graft to the DLN, it was investigated whether 
this would affect graft survival, as a result of reduced priming of allo-reactive T cells, in 




To this end, BALB/c kidneys were transplanted into EYFP recipients injected with either 
anti-ICAM-1 antibody or vehicle 30 minutes before transplantation. Recipients were also 
splenectomised to remove alternative locations for T cell priming. The remaining native 
kidney was removed at day 7, rendering the transplanted kidney life-sustaining. Graft 








Anti-ICAM-1 antibody treatment in splenectomised recipients resulted in indefinite graft 
survival of fully allogeneic donor grafts in some recipients (median survival time 
(MST)>100 days). By contrast, splenectomy only and anti-ICAM-1 antibody treatment 
only had reduced beneficial effects (MST=10 days, p=0.1676; and MST=8.5 days, 






Figure 3.6- Survival of kidney allografts in recipients treated with anti-ICAM-1 antibody.  
Kidneys from BALB/c mice were transplanted into splenectomised or non-splenectomised 
recipients treated with either anti-ICAM-1 antibody or vehicle control. Splenectomised recipients 
treated with anti-ICAM-1 antibody survived longer than non-splenectomised recipients treated 
with anti-ICAM-1 antibody, p=0.0276. 
 
 
Kidney function was measured at weekly intervals after transplantation using an assay 
for BUN (Figure 3.7). In the anti-ICAM-1 antibody plus splenectomy group BUN from all 
long-term surviving recipients was within the normal range until the end of the experiment 
(100 days); (Figure 3.7 d). Conversely, in the splenectomy only group, although three 
recipients survived long-term, the BUN steadily increased with time until the mice 






Figure 3.7- Blood urea nitrogen (BUN) measurements from kidney allograft recipients.  
(a) BUN of mice receiving vehicle treatment only with no splenectomy where most recipients were 
sacrificed at an early time point due to poor graft function with high BUN. (b) BUN of mice receiving 
anti-ICAM-1 antibody-treatment only and no splenectomy where all recipients were sacrificed at 
an early time point due to poor graft function with high BUN. (c) BUN of mice receiving 
splenectomy only where those surviving past day 10 had increasing BUN. (d) BUN of mice 
receiving anti-ICAM-1 antibody-treatment and splenectomy where 60% of recipients survived until 
the end of the experiment with normal graft function and BUN within normal range. Normal range 




Histological examination of donor grafts transplanted into anti-ICAM-1 antibody-treated 
splenectomised recipients showed well preserved tubules. Areas of dense mononuclear 
cell infiltration, suggestive of tertiary lymphoid organs, were also found (Figure 3.8), in 
accordance with our previous description of histological changes in tolerant murine 
kidney allografts (186). Thus, reducing DPL trafficking via lymphatics in the early post-
transplantation period improved graft function and survival, but only if the recipient spleen 






Figure 3.8- Histology of long-term surviving kidney grafts.  
Kidney grafts were harvested 100 days after transplantation and stained with periodic acid Schiff’s 
(PAS) to demonstrate tissue structure and cellular infiltration. Representative PAS staining on 
long-term surviving kidney allograft from splenectomised anti-ICAM-1 antibody-treated recipient, 
showing presence of dense mononuclear cell infiltration, suggestive of tertiary lymphoid organs 




3.4 Quantification of T cell infiltrate in anti-ICAM-1 antibody-treated 
allogeneic kidney grafts 
Rejection and tolerance of allografts is mediated by T cells which have encountered 
donor antigen. Donor-specific T cells that have been activated in recipient SLO traffic 
back to the graft to exert their effector functions. In order to clarify whether the positive 
effects of anti-ICAM-1 antibody treatment in splenectomised recipients was due to a 
reduction in T cell priming in DLN as a result of reduced trafficking of DPL; the graft T 
cell response was analysed.  
 
Kidney grafts were harvested from recipients having either received anti-ICAM-1 
antibody therapy plus splenectomy or vehicle plus splenectomy, 5 days following 
transplantation, and the T cell infiltrate was quantified using flow cytometry (Figure 3.9). 
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Day 5 was chosen as it was around the time of heavy T cell infiltration, but before the 




Figure 3.9- Experimental design of assessment of T cell infiltration of kidney allografts in anti-
ICAM-1 antibody-treated recipients. 
 
 
Kidney grafts were digested and the leukocytes obtained by density centrifugation. T 
cells were gated as presented in Figure 3.10; lymphocytes were broadly gated in the 
forward vs. side scatter plot and then further defined as single cells. These cells were 
further defined as CD45+ and dead cells were excluded. They were further categorized 






Figure 3.10- Gating strategy for T cells.  
Kidney grafts were harvested at day 5 post-transplantation, digested and the leukocytes 
recovered. Cells were gated according to (a) scatter properties, (b) single cells, (c) dead cell stain 






Grafts from recipients treated with anti-ICAM-1 before transplantation had a 
similar degree of T cell infiltration as grafts from those that received vehicle treatment. 
There was no difference in the size of the T cell population (CD45 CD3 double positive 
population) as a proportion of the total between anti-ICAM-1 antibody-treated recipients 
and  vehicle control-treated recipients (6.37±1.822% vs. 4.63±0.7%, p=0.4717); (Figure 
3.11 a). In addition, there was no difference in the size of the CD4+ and CD8+ T cell 
populations as a proportion of the total between anti-ICAM-1 antibody-treated and 
vehicle control-treated recipients (CD4+, 2.560±0.86 vs. 2.613±0.35%, p=0.9617; CD8, 






Figure 3.11- Size of T cell populations within kidney grafts at day 5 post-transplantation 
(proportion).  
Kidney grafts were harvested at day 5 post-transplantation, digested and the leukocytes 
recovered. Cells were analysed for expression of CD3, CD4 and CD8 by flow cytometry. There 
were no differences in the size of the (a) total T cell populations, p=0.4717 (b) CD4+ T cell 
populations, p=0.9617 and (c) CD8+ T cell populations, p=0.2299 as a proportion of the total 
between anti-ICAM-1 antibody-treated and vehicle control-treated recipients. Each data point 




These results were confirmed by calculation of the number of CD3+, and CD3+CD4+, and 
CD3+CD8+ cells per gram of tissue in each sample. Absolute numbers were calculated 
using the weight of the portion of the kidney used for analysis. There was no difference 
in the number of CD3+, CD3+CD4+ or CD3+CD8+ cells between grafts from anti-ICAM-1 
antibody-treated and vehicle control-treated recipients (CD3+, 11214±2676 vs. 
6114±13967 cells/gram, p=0.2143; CD4+, 4517±1164 vs. 3647±781 cells/gram, 








Figure 3.12- Size of T cell populations within kidney grafts at day 5 post-transplantation (absolute 
number).  
Kidney grafts were harvested at day 5 post-transplantation, digested and the leukocytes 
recovered. Cells were analysed for expression of CD3, CD4 and CD8 by flow cytometry. There 
were no differences in the number of (a) total T cells, p=0.2143 (b) CD4+ T cells, p=0.5930 and 
(c) CD8+ T cells, p=0.1087 between anti-ICAM-1 antibody-treated and vehicle control-treated 




The activation status of the T cells infiltrating kidney allografts in anti-ICAM-1 antibody-
treated and vehicle control-treated recipients was then assessed. CD44 is frequently 
used as a marker of T-cell activation because T cells upregulate expression of this 
molecule following activation (228). There was no difference in expression levels of 
CD44 on CD4+ and CD8+ T cells from anti-ICAM-1 treated grafts compared with vehicle 
control-treated graft, (MFI (median fluorescence intensity) of CD44 on CD4+ T cells, 
8140±361 vs. 6287±838, p=0.0737; MFI of CD44 on CD8+ T cells, 5931±207 vs. 






Figure 3.13- Activation status of T cells infiltrating kidney grafts at day 5 post-transplantation. 
Kidney grafts were harvested at day 5 post-transplantation, digested and the leukocytes 
recovered. T cells were analysed by flow cytometry for expression of the activation marker, CD44. 
There was no difference in expression of CD44 on graft-infiltrating (a) CD4+, p=0.0737 and (b) 
CD8+ T cells, p=0.0832 between anti-ICAM-1 antibody-treated and vehicle control-treated 
recipients. Each data point represents one mouse. MFI (median fluorescence intensity). 
 
 
In addition, the numbers of Foxp3+ cells within the grafts from both groups at day 5 were 
investigated. The expression of the Treg-specific transcription factor, Foxp3, was 
examined histologically and no difference in number of Foxp3-expressing cells was 
found between the anti-ICAM-1-treated and vehicle-treated groups (13.55±2.32 vs. 








Figure 3.14- Foxp3 expression within kidney grafts at day 5 post-transplantation.  
Kidney grafts were harvested at day 5 post-transplantation and snap frozen sections were stained 
immunohistochemically for expression of the Treg specific transcription factor, Foxp3. (a) There 
was no difference in the average number of Foxp3 positive cells per medium powered field within 
graft tissue between anti-ICAM-1 antibody-treated and vehicle control-treated recipients, 
p=0.6072. (b) Representative image showing Foxp3 positive cells distributed throughout the 
parenchyma of a kidney graft. Original magnification 200x. At least 10 random fields of view were 




In conclusion, there was no difference in the T cell infiltration of kidney allografts between 
recipients that received anti-ICAM-1 antibody treatment compared with those that 
received vehicle control treatment. The proportions and absolute numbers of the CD4+ 
and CD8+ T cell populations were similar between the two groups. In addition, there was 
no significant difference in expression levels of CD44 on T cells between anti-ICAM-1-
treated and vehicle control-treated recipients. And finally the numbers of Tregs were the 





This chapter presents results from an experiment using anti-ICAM-1 antibody treatment 
in a murine kidney transplant model in order to test the contribution of post-
transplantation trafficking of DPL via the lymphatic route. Recipient mice were treated 
with an anti-ICAM-1 antibody or saline before transplantation and their spleens removed 
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so that the lymphatic route could be assessed in isolation. Treatment with anti-ICAM-1 
antibody led to a reduction in donor-derived DNA in the recipient DLN 24 hours post-
transplantation; and long-term graft survival with normal function in some recipients. The 
T cell infiltrate within the graft was also assessed at day 5 after transplantation, and no 
significant differences in proportions and numbers of CD4+ and CD8+ T cells were found 




Efficient trafficking of immune cells is essential for the induction of the allo-immune 
response in solid organ transplantation; in particular the movement of DPL from the graft 
to the local DLN, where they encounter and activate cognate T cells, is the driving force 
of acute rejection.  
 
Previous work from our group has visualised lymph flow from the graft to DLN in 
heterotopic murine heart transplantation, and has demonstrated the presence of donor 
specific allo-reactive T cells in these lymph nodes, but not in other non-draining lymph 
nodes (176). Here, the aim was to establish whether blocking the traffic of cells from the 
graft to the DLN via the lymphatic route would affect the survival of allografts. 
 
Studies on the fate of DPL after transplantation are limited by technical difficulties in 
tracing these cells in vivo in an accurate and quantitative manner. This is in part due to 
the small population size, and the lack of reliable markers. Most in vivo tracking studies 
rely on the use of the CD45.1/CD45.2 alloantigen system, and employ flow cytometry to 
quantify cells of donor origin (229). This often means that tissue from multiple recipient 
mice are pooled together so that the donor population can be seen reliably on the flow 
cytometry plot. Quantitative real-time PCR, amplifying genomic DNA targets, is more 
sensitive for quantification of small populations as in theory only one copy of the target 
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gene is needed for amplification to occur and be visualised by fluorescence. Indeed, this 
technique is successfully used for the assessment of haematological disease (230), and 
for diagnosis of viral infection in the clinic (231). This technique has been used here to 
accurately quantify the number of donor cells that have trafficked to the DLN of 
recipients. 
 
An ICAM-1-dependant mechanism for immune cell trafficking via the lymphatic system, 
in inflammatory conditions has been confirmed by others (129), but whether or not this 
pathway is important in the immune response following transplantation has not yet been 
investigated. Here, it is shown that treatment with an ICAM-1 blocking antibody 
immediately prior to transplantation reduced trafficking of DPL to the DLN. When used 
in recipients of kidney allografts with intact spleens, this did not result in graft 
prolongation. This is not surprising as donor passenger leukocytes can leave donor 
organs via the blood and traffic to the spleen of recipient where they can prime T cells 
(88), indicating that the blood and lymphatic routes of antigen trafficking to SLO can 
compensate for each other. Removal of the spleen of the recipient removed this route 
and resulted in significant prolongation of graft survival in this model. One recipient in 
the vehicle only group rejected the donor graft later, at 81 days rather than around 8 to 
10 days. This is not unusual; late rather than early rejection in a small percentage of 
recipients has been described in this model (232). 
 
These results point to an active role for ICAM-1 in trafficking of DPL following 
transplantation; blocking of this pathway resulting in a dampened allo-immune response 
and long-term survival of allografts. This is consistent with observations by Ziegler and 
colleagues, who demonstrated suppression of antigen-induced T-cell proliferation when 





Other pathways, in addition to the direct antigen presentation pathway, such as the 
indirect and semi-direct pathways of antigen presentation, are important in the rejection 
response. The demonstration here that blocking the direct pathway resulted in prolonged 
graft survival does not mean that the other pathways of antigen presentation are not 
important. This would be particularly true in human organ transplantation where the 
rejection response is expected to be more pronounced than that seen in laboratory 
animals (234). 
 
Anti-ICAM-1 antibody treatment may have other effects in addition to blockade of DPL 
trafficking; and therefore, the beneficial effect of anti-ICAM-1 antibody treatment seen 
here may not be solely attributed to its effect on DPL trafficking. ICAM-1 is a known 
molecule involved in T-cell transmigration into tissue during inflammation (235), as well 
as a co-stimulator of T cells (reviewed in (236)), and indeed blocking studies have 
previously been performed in transplantation models to confirm the role of ICAM-1 in this 
context (226). However, the focus of this work was to assess the role of ICAM-1-
mediated lymphatic trafficking in the immediate post-transplant period, and thus 
treatment was restricted to one pre-transplantation injection, rather than repeat injections 
for the duration of the experiment. Anti-ICAM-1 antibody treatment was not expected to 
have any significant effect on T cell infiltration into the graft, which happens later after 
transplantation. 
 
If indeed, reduced DPL trafficking and therefore reduced T-cell activation was the sole 
mechanism responsible for the graft prolongation effect seen, then one would expect 
reduced T cell infiltration into the anti-ICAM-1-treated donor grafts. However this was not 
the case. The T cell infiltrate at day 5 following transplantation was the same in anti-
ICAM-1-treated recipients compared with vehicle control-treated recipients. 
Accumulation of lymphocytes in renal allografts that eventually survive long-term is a well 
described phenomenon, where they have been postulated to play an active role in the 
graft-protective effect (186). It is also important to note that assessing T-cell infiltration 
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using flow cytometry, although resulting in a more accurate quantification of cell numbers 
than using standard immunohistochemistry, does not give any information on the location 
of the cells within the kidney graft. The presence of mononuclear cells within the 
interstitium does not always correlate with poor graft function; lymphocytes need to be 
present within the tubules for the diagnosis of tubulitis and therefore rejection. Without 
this information, it is difficult to make assumptions on the impact of the T cell infiltrate on 
graft function and rejection. The superior graft survival in the anti-ICAM-1 antibody-
treated recipients could be because the reduction in DPL trafficking to DLN in the 
immediate post-transplantation period led to sub-optimal priming of T cells in this 
location; however, more work is needed to fully elucidate the mechanism. 
 
In addition, blockade of the ICAM-1/LFA-1 axis has been postulated to result in T cells 
being released from the DLN more readily (237). Indeed, Reichardt et al. showed that 
interactions between T cells and lymphatic vessels in the lymph node via LFA-1 and 
ICAM-1 respectively, are essential for retention of T cells in the lymph node; and 
concluded that LFA-1/ICAM-1 interactions within the lymph node enhance antigen-
specific responses because of increased likelihood of T cell encounter of cognate antigen 
(237). Therefore, it is possible that by blocking this interaction with an anti-ICAM-1 
antibody in this model, sub-optimally primed T cells leave the DLN more readily and 
traffic to the graft. 
 
Additionally, the anti-ICAM-1 antibody administered to the recipient has, in theory, two 
locations of potential action; the graft lymphatics and the recipient lymphatics. More 
detailed analysis would be needed to assess the contribution of these two locations of 
DPL trafficking to the allo-immune response. 
 
This chapter highlights the importance of the lymphatic route of DPL trafficking in the 
induction of the allo-immune response, and reveals ICAM-1-mediated lymphatic 











Lymphatic vessels within the graft parenchyma are the point of entry of DPL into the 
recipient lymphatic system. We have previously demonstrated the route of lymph flow 
from here to the DLN in a murine model of heterotopic heart transplantation (176). The 
previous chapter explored the contribution of the lymphatic system to the allo-response 
by pharmacologically blocking ICAM-1, a key molecule involved in the transmigration of 
immune cells across the lymphatic endothelium.  
 
In this chapter, an alternative approach was used to investigate whether hindering 
lymphatic vessel function would improve graft outcome due to altered trafficking of DPL 
in the immediate post-transplantation period. Various agents are available to target 
lymphatic function systemically such as anti-CCL21 (179) and anti-VEGFR3 (178); 
however, their effects are limited to the treatment period and they target mainly the 
development of new lymphatic vessels, rather than lymphatic vessels that are already 
within the donor grafts. Here, a specific mouse strain which has a spatially and temporally 
conditional knock-out of ephrin B2 was used. The eph/ephrin signalling pathway controls 
multiple cell functions including migration and cytoskeletal organisation (238). 
Particularly in LECs, ephrin B2 signalling via ephB4 controls lymphangiogenesis and 
lymphatic valve maintenance (117). The mouse strain used here has a cre recombinase 
linked to the Prox1 transcription factor and a floxed ephrin B2 gene, thus allowing specific 
deletion of ephrin B2 in LECs. According to the original publication using this strain, 
following tamoxifen administration efficient ephrin B2 deletion is observed in the 
lymphatic endothelium within 1 week (102); and these mice lack the capacity to grow 
new functional lymphatic vessels and existing lymphatic vessels become functionally 
ineffective, dilate and disintegrate in situ. 
 
When using these mice for the work presented here, it was observed that from day ten 
following tamoxifen administration ephrin B2 deficiency becomes fatal. Therefore, it was 
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decided that for all experiments ephrin B2-/- mice would be harvested at day eight 
following tamoxifen treatment to ensure that the knockout had no effect on the function 
of organs to be used in transplantation models. 
Using the ephrin B2-/- mouse as an organ donor in transplantation therefore allowed the 
study of the effect of the disruption of donor lymphatics on graft survival.  
 
4.2 Deletion of ephrin B2 following tamoxifen treatment 
Mice from the ephrin B2 colony were genotyped before and after tamoxifen treatment to 
assess the status of the floxed ephrin B2 gene and to demonstrate successful deletion. 
At weaning ear samples were taken and PCR performed using primer sequences a and 
b (as outlined in section 2.3.1), yielding a 380 bp product if the mice were homozygous 
for floxed ephrin B2. In addition, 8 days after tamoxifen treatment, another ear sample 
was taken and PCR performed using primer sequences a and c, yielding a 320 bp 








Figure 4.1- PCR to demonstrate successful deletion of ephrin B2.  
PCR was performed on DNA of cre positive mice homozygous for the floxed ephrin B2 gene 
before and after tamoxifen treatment. Before tamoxifen treatment (-t), PCR using primer 
sequences a and b yields a 380 bp product, demonstrating that both ephrin B2 alleles are floxed. 
PCR using primer sequences a and c after tamoxifen treatment (+t) yields a 320 bp product 
demonstrating deletion of the ephrin B2 gene. (a) Schematic of floxed ephrin B2 gene showing 
location of primer sequence binding (b) Representative images of DNA products from both PCR 
assays on agarose gels. Lanes 2 and 4 show a 380 bp band demonstrating that the mice are 
homozygous for floxed ephrin B2; this band is not present after tamoxifen treatment (lanes 1 and 
3). Lanes 6 and 8 show a 320 bp product demonstrating that floxed ephrin B2 has been deleted 




4.3 Effect of ephrin B2 deficiency on lymphatic morphology within 
organs 
In order to investigate the effect of ephrin B2 deficiency in lymphatic endothelial cells the 
gross appearance of the lymphatic networks within organs that would subsequently be 
used as donor organs in transplantation models was studied. For the experiments 
discussed in this chapter control mice were either: wild-type for both ephrin B2 alleles 
(i.e. non-floxed) and cre positive (referred to as wild-type), or had floxed ephrin B2 alleles 
but were cre negative (referred to as control). The term ephrin B2-/- refers to donor mice 
which have floxed ephrin B2 alleles, are cre positive and treated with tamoxifen, meaning 
that the ephrin B2 gene has been deleted in LECs. Ephrin B2-/- and wild-type mice were 
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treated with tamoxifen; and eight days later skin, heart and kidney tissue was harvested 
and analysed by immunohistochemistry. Frozen tissue sections were stained for the 
lymphatic marker LYVE-1, and lymphatics analysed in terms of density and size.  
 
 
The density and size of lymphatic vessels in each organ was quantified. There was no 
difference between the ephrin B2-/- and wild-type groups, in terms of lymphatic density 
(skin, 1.00±0.17 vs. 0.92±0.17 vessels per medium powered field, p=0.7216; heart, 
0.64±0.13 vs. 0.69±0.01, p=0.7372; kidney, 0.40±0.05 vs. 0.27±0.06, p=0.2784); (Figure 
4.2). In addition, there was no difference in average vessel size between the two groups 
(skin, 8656±2388 vs. 4794±563.2 arbitrary values, p=0.1541; heart, 7833±1867 vs. 




Figure 4.2- Quantification of lymphatic vessel density in skin, heart and kidney.  
Skin, heart and kidney tissue was harvested from ephrin B2-/- and wild-type mice 8 days following 
tamoxifen treatment and stained for the lymphatic marker, LYVE-1.There were no differences in 
the number of vessels in skin (p=0.7216), heart (p=0.7372) and kidney (p=0.2784) tissue after 
tamoxifen treatment between wild-type (WT) and ephrin B2-/- (-/-). At least 5 random fields of view 
were analysed per section. Bars represent the average number of vessels per section. One 






Figure 4.3- Quantification of lymphatic vessel size in skin, heart and kidney.  
Skin, heart and kidney tissue was harvested from ephrin B2-/- and wild-type mice 8 days following 
tamoxifen treatment and stained for the lymphatic marker, LYVE-1.There were no differences in 
skin (p=0.1541), heart (p=0.7299) and kidney (p=0.3582) lymphatic vessel size after tamoxifen 
treatment between ephrin B2-/-(-/-) and wild-type (WT) mice. At least 5 random fields of view were 
analysed per section. Bars represent the average size of vessel per section. One section of tissue 




Figure 4.4- LYVE-1 staining of skin, heart and kidney tissue from tamoxifen-treated wild-type (WT) 
and ephrin B2-/- (-/-) mice.  
Skin, heart and kidney tissue was harvested from ephrin B2-/- and wild-type mice 8 days following 
tamoxifen treatment and stained for the lymphatic marker, LYVE-1. Representative images of 
LYVE-1 staining from all tissues demonstrates no difference in size or density of lymphatics 





Collectively, these observations suggested that despite the fact that following deletion of 
ephrin B2 , mice eventually die as a result of lymphatic dysfunction, the gross appearance 
of the lymphatic vasculature in skin, heart and kidney at day eight is normal in 
comparison to wild-type mice, and the knock-out of ephrin B2 had no effect on lymphatic 
vessel density and size. 
 
 
4.4 Phenotype of graft antigen presenting cells after tamoxifen 
treatment 
As the aim was to use ephrin B2-/- mice as organ donors in transplantation models, it was 
essential to confirm that the knockout of ephrin B2 in LECs had no effect on the leukocyte 
composition of the donor organs being used in these models. The reason for this being 
that a reduction in number or antigen presenting capacity could lead to enhanced survival 
of ephrin B2-/- grafts. To this end, cardiac leukocytes from tamoxifen treated wild-type 




Figure 4.5- Experimental design for assessment of antigen presenting cell numbers and 
phenotype in ephrin B2-/- and wild-type mice. 
 
 
Hearts from wild-type and ephrin B2-/- mice were digested and the leukocytes obtained 
by density centrifugation; these cells were then analysed by flow cytometry. The CD45+ 
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leukocytes from each sample were analysed by first gating out debris from the digested 
tissue using the forward and side scatter properties of the sample. Subsequently any 
doublets were excluded from analysis and the CD45+ live population gated on for further 
analysis. Within the live CD45+ gate the proportions of CD11b+ and CD11c+ cells were 
calculated (Figure 4.6 a to e). 
 
 
Figure 4.6- Gating strategy for heart antigen presenting cells.  
Hearts were harvested 8 days after tamoxifen treatment; digested and the leukocytes recovered. 
Cells were gated according to (a) scatter properties, (b) single cells, (c) dead cell stain exclusion, 
(d) CD45 expression, and either; (e) CD11c or (f) CD11b expression. Solid black lines indicate 
where positive gates were placed.   
 
 
The proportions of CD11b+ and CD11c+ cells within the CD45+ gate were analysed and 
no significant differences were found between the two groups in the proportions of these 
two APC populations. The proportion of CD11b+ cells in the CD45+ gate was 33.6±2.8% 
in ephrin B2-/- hearts, compared with 50.52±8.93% in wild-type hearts (p=0.1089); (Figure 
4.7 a). The proportion of CD11c+ cells in the CD45+ gate was 8.21±1.5% in ephrin B2-/- 





Figure 4.7- Proportions of antigen presenting cells in heart tissue from ephrin B2-/- (-/-) and wild-
type (WT) mice after tamoxifen treatment.  
Hearts were harvested 8 days after tamoxifen treatment, digested and the leukocytes recovered. 
Cells were gated according to Figure 4.6 and analysed for expression of CD11c and CD11b. 
There were no differences in the size of (a) the CD11b+ population, p=0.1089, and (b) the CD11c+ 
population, p=0.2001 as a proportion of the total CD45+ leukocyte population between ephrin B2-
/- and wild-type mice. Each data point represents one mouse.  
 
 
In order to confirm the above finding, the absolute numbers of CD11b+ and CD11c+ cells 
within the heart leukocyte preparations were calculated using the values calculated when 
counting the cells during preparation of the sample at the stage following density 
centrifugation. There was no significant difference in the numbers of CD11b+ cells 
between ephrin B2-/- and wild-type heart leukocytes (3245±3799 vs. 10743±3642 
p=0.0910); (Figure 4.8 a). Similarly, there was no significant difference in the numbers 
of CD11c+ cells between ephrin B2-/- and wild-type heart leukocytes (689±222 vs. 








Figure 4.8- Absolute numbers of antigen presenting cells in heart tissue from ephrin B2-/- (-/-) and 
wild-type (WT) mice after tamoxifen treatment.  
Hearts were harvested 8 days after tamoxifen treatment, digested and the leukocytes recovered. 
Cells were gated according to Figure 4.6, analysed for expression of CD11c and CD11b, and the 
absolute numbers calculated based on the total cells recovered from the tissue. There were no 
differences in the numbers of (a) CD11b+ cells, p=0.0910, and (b) CD11c+ cells, p=0.2225 
between ephrin B2-/- and wild-type mice. Each data point represents one mouse.  
  
 
DCs become activated by local inflammation leading them to adopt a ‘mature’ phenotype. 
Following maturation, DCs upregulate expression of MHC class II and co-stimulatory 
molecules, such as CD80, to enhance antigen presentation to T cells, and migratory 
molecules, such as CCR7, to aid trafficking to SLO. Therefore, the CD11c+ and CD11b+ 
populations within heart tissue of wild-type and ephrin B2-/- mice were studied to examine 
whether or not the absence of ephrin B2 on LEC had affected the phenotype of heart 
resident DCs. As expected, MHC class II expression by DCs (both CD11c+ and CD11b+) 
was low, and there was no statistically significant difference in the proportion of CD11c+ 
and CD11b+ cells that were MHC II+ between cells isolated from ephrin B2-/- hearts 
compared with wild-type hearts (CD11c+: 9.93±2.64 vs. 9.80±4.35, p=0.9793, CD11b+: 
0.51±0.42 vs. 0.83±0.56, p=0.6588); (Figure 4.9 e and Figure 4.10 e respectively). The 
heart resident antigen presenting cell populations were compared to those recovered 
from transplant recipient spleens, where the CD11c and MHC class II expression are 
both high (Figure 4.9 b); to demonstrate that heart resident CD11c+ and CD11b+ 






Figure 4.9- Phenotype of heart resident CD11c+ cells wild-type (WT) and ephrin B2-/- (-/-) hearts 
following tamoxifen treatment.   
Hearts were harvested 8 days after tamoxifen treatment, and spleen were harvested 1 days after 
allogeneic heart transplantation, digested and the leukocytes recovered. Cells were gated 
according to Figure 4.6 and analysed for expression of CD11c and MHC class II. Heart leukocytes 
were compared to (a) naïve spleen leukocytes and (b) spleen leukocytes recovered from a heart 
transplant recipient to demonstrate immature status of CD11c+ dendritic cells. There was no 
difference in the proportion of CD11c+ MHC II+ double positive cells between (c and e) wild-type 
and (d and e) ephrin B2-/- hearts following tamoxifen treatment. (e) Each data point represents 





Figure 4.10- Phenotype of heart resident CD11b+ cells wild-type (WT) and ephrin B2-/- (-/-) hearts 
following tamoxifen treatment.   
Hearts were harvested 8 days after tamoxifen treatment, digested and the leukocytes recovered. 
Cells were gated according to Figure 4.6 and analysed for expression of CD11b and MHC class 
II. Heart leukocytes were compared to (a) naïve spleen leukocytes and (b) spleen leukocytes 
recovered from a heart transplant recipient to demonstrate immature status of CD11b+ antigen-
presenting cells. There was no difference in the proportion of CD11b+ MHC II+ double positive 
cells between (c and e) wild-type and (d and e) ephrin B2-/- hearts following tamoxifen treatment. 
(e) Each data point represents one mouse. p=0.9793 
 
 
Therefore, deficiency of ephrin B2 in LECs within heart tissue had no discernible impact 




4.5 Survival of ephrin B2-/- grafts in allogeneic recipients 
Lymphatic vessels in the donor organ serve as an entry point for DPL into the recipient, 
as from here it is hypothesised that they leave the graft and are eventually picked up by 
recipient lymphatics and traffic to the DLN. Therefore, it was decided to assess the effect 
of knocking out ephrin B2, an essential molecule in lymphatic vessel function, in graft 




Donor mice were administered 5µg tamoxifen intraperitoneally, and after 8 days skin, 









Whilst skin allografts from control donors transplanted onto BALB/c splenectomised 
recipients were rejected acutely (MST=10 days), skin from ephrin B2-/- donors survived 
significantly longer on BALB/c recipients with or without intact spleens (splenectomy: 






Figure 4.12- Survival of ephrin B2-/- skin on allogeneic recipients.  
Skin from ephrin B2-/-and control mice was transplanted onto BALB/c recipients that had either 
received a splenectomy or had intact spleens. Ephrin B2-/- skin survived significantly longer than 
control skin. *** p<0.0001 
 
 
Heart allografts from ephrin B2-/- donors also survived significantly longer in 
splenectomised BALB/c recipients (MST=26 days) than control hearts (MST=12 days, 
p=0.0021) and ephrin B2-/- hearts in non-splenectomised recipients (MST=13.5 days, 






Figure 4.13- Survival of ephrin B2-/- hearts in allogeneic recipients.  
Hearts from ephrin B2-/- and control mice were transplanted into BALB/c recipients that had either 
received a splenectomy or had intact spleens. Ephrin B2-/- hearts survived significantly longer 
than control hearts. ** p<0.01 
 
 
Kidneys from ephrin B2-/- donors survived indefinitely in splenectomised BALB/c 
recipients (MST>100 days) whereas control kidneys rejected acutely (MST=8 days, 
p=0.0237). Ephrin B2-/- kidneys in non-splenectomised recipients has an MST of 70 
(p=0.0736); (Figure 4.14). Therefore, disruption of donor lymphatics had a significant 
impact on graft survival, with all organs assessed (skin, heart, and kidney) surviving 







Figure 4.14- Survival of ephrin B2-/- kidneys in allogeneic recipients.  
Kidneys from ephrin B2-/- and control mice were transplanted into BALB/c recipients that had 
either received a splenectomy or had intact spleens. Ephrin B2-/- kidneys survived significantly 
longer than control kidneys when the recipient was splenectomised. * p=<0.05 
  
 
Ephrin B2-/- kidneys that survived long-term in splenectomised recipients had normal 
kidney function, as demonstrated by a mean BUN of 9.45±2.9 mmol/L at the end of the 
experiment (100 days, normal range 0-10 mmol/L). In addition, histological analysis of 
sections from long-term surviving ephrin B2-/- kidneys showed small well defined areas 
of dense mononuclear cell infiltration, suggestive of TLOs, well preserved tubular 
structure, and mild lymphocyte infiltration of tubules (Figure 4.15). These histological 
changes have previously been shown in a model of kidney allograft tolerance in our 






Figure 4.15- Histology of long-term surviving ephrin B2-/- kidney grafts. 
Kidney grafts were harvested 100 days after transplantation and stained with PAS to demonstrate 
tissue structure and cellular infiltration. Representative images showing (a) presence of dense 
mononuclear infiltrates suggestive of TLOs (arrow), (b, c) good preservation of tubular structure 




In addition, immunohistochemical analysis of long-term surviving ephrin B2-/- kidney 
grafts revealed the presence of lymphatic vessels (Figure 4.16). Lymphatic vessels were 






Figure 4.16- LYVE-1 staining of long-term surviving ephrin B2-/- kidney grafts. 
Kidney grafts were harvested 100 days after transplantation and stained for the lymphatic marker 
LYVE-1. Representative images showing presence of lymphatic vessels in ephrin B2-/- kidney 




4.6 Quantification of DPL trafficking using real-time PCR 
Having demonstrated that organs with the ephrin B2 knockout in LECs survived longer 
after transplantation than organs without the knockout, the effect of this on post 
transplantation trafficking of DPL was assessed. As ephrin B2 is essential for lymphatic 
function, it was hypothesised that the knockout would result in a different trafficking 
pattern of cells out of the graft in the immediate post-transplantation period. 
 
To determine the effect of the ephrin B2 knockout on DPL trafficking, ephrin B2-/- hearts 
or wild-type cre positive hearts were transplanted into BALB/c recipients, and the 
mediastinal lymph nodes (DLN for heterotopic cardiac transplantation) were harvested 





Figure 4.17- Experimental design for quantification of DPL trafficking form ephrin B2-/- and wild-




The proportion and absolute number of donor cells in the mediastinal lymph nodes 24 
hours post–transplantation was determined by real-time PCR for the donor-specific 
gene, cre. Quantitative real-time PCR was used to quantify donor cells in recipient lymph 
nodes because of its sensitivity and accuracy. The genomic target to be amplified was 
the donor specific gene, cre, which is inserted into the genome of the donor mice as a 
transgene, and thus only donor DNA would be amplified. A standard curve was 
generated for each data point with DNA isolated from the specific cre positive donor’s 
mediastinal lymph nodes and the proportion of DNA in transplant recipient DLN that was 
donor-derived was quantified from the standard curve. This data could then be converted 
to the number of cells of donor origin in the recipient sample by using the c-value. 
 
There was no significant difference in the absolute number of donor-derived cells 
(140.0±32.34 vs. 169.6±52.67, p=0.6409); (Figure 4.19) or density of donor-derived DNA 
(0.012±0.004 vs. 0.016±0.005, p=0.5830); (Figure 4.18) in recipient DLN from animals 
that received a wild-type graft compared with those that received an ephrin B2-/- graft. 
Thus, knock-out of ephrin B2 in LECs of the graft had no impact on the kinetics of donor 






Figure 4.18- Quantification of donor DNA within recipient DLN 24 hours post-transplantation. 
Hearts from tamoxifen-treated wild-type (wt) or ephrin B2-/- (-/-) were transplanted into 
splenectomised BALB/c recipients and 24 hours later the mediastinal lymph nodes were 
harvested, subjected to DNA extraction and analysed using a real-time quantitative PCR assay 
for a the donor specific gene, cre. The proportion of the total amount of recipient draining lymph 
node DNA that was of donor origin was calculated by comparing ct values to standard curves 
generated from donor lymph node DNA. There was no difference in the proportion of donor-
derived DNA within recipient DLN DNA between recipients receiving wild-type and ephrin B2-/- 










Figure 4.19- Quantification of donor cells within recipient DLN 24 hours post-transplantation. 
Hearts from tamoxifen-treated wild-type (wt) or ephrin B2-/- (-/-) were transplanted into 
splenectomised BALB/c recipients and 24 hours later the mediastinal lymph nodes were 
harvested, subjected to DNA extraction and analysed using a real-time quantitative PCR assay 
for a the donor specific gene, cre. The proportion of the total amount of recipient draining lymph 
node DNA that was of donor origin was calculated by comparing ct values to a standard curve.  
The number of donor-derived cells was calculated using the c-value which corresponds to the 
total amount of DNA per cell. There was no difference in the number of donor-derived cells in 
recipient DLN between recipients receiving wild-type and ephrin B2-/- grafts, p=0.6409  Each data 




4.7 Further evaluation of ephrin B2 deficiency on DPL trafficking 
The previous experiment confirmed that there was no difference in donor cell trafficking 
from the graft to the recipient DLN in the immediate post-transplantation period between 
ephrin B2-/- and wild-type heart grafts, despite the prolongation of survival observed in 
recipients of ephrin B2-/- grafts. To further understand the mechanism for the graft 
prolongation effect observed, a double skin transplant experiment was performed, where 
recipient mice received both an ephrin B2-/- and wild-type graft at the same time. This 
experiment would demonstrate whether or not the effect on survival of the ephrin B2 
knockout was limited to the area of the graft, or if the ephrin B2-/- graft was able to exert 
a dominant protective effect systemically. The experiment in the previous section was 
limited to one time point after transplantation (24 hours) after transplantation. Indeed, if 
there was reduced trafficking of DPL from ephrin B2-/- grafts, in this experiment the ephrin 
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B2-/- graft may reject at a faster tempo because of the presence of the wild-type graft. As 
both grafts will elicit the same allogeneic response because they originate from the same 
strain, T cells activated by DPL from either skin graft can carry out the rejection of both 
skins. The T cells activated in the DLN will enter the blood and have the ability to traffic 
to either of the grafts to elicit effector functions. 
 
To this end, recipient BALB/c mice were transplanted with two skin grafts: either two wild-
type grafts, two ephrin B2-/- grafts, or one wild-type and one ephrin B2-/- graft. Both wild-
type and ephrin B2-/- donor mice were treated with tamoxifen eight days before 
transplantation (as in previous experiments), and tail skin was harvested and grafted 




Figure 4.20- Experimental design for double skin transplantation.  
Recipient BALB/c mice received two skin transplants, one from an ephrin B2-/- donor and one from 
a wild-type donor, both having received tamoxifen treatment. Recipients also received a 




Firstly, in order to assess whether or not ephrin B2-/- grafts retain their survival advantage 
over wild-type grafts when two skin grafts are transplanted onto one recipient, BALB/c 
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recipients were transplanted with two grafts of the same type i.e. either two wild-type 
grafts or two ephrin B2-/-grafts.  
 
When either two wild-type or two ephrin B2-/-grafts were transplanted onto the same 
recipient the rate of rejection was similar to that observed in the single transplant 
experiment (section 4.4), with ephrin B2-/- skin surviving longer (MST=18 days) than wild-
type skin (MST=15 days, p=0.1179) on allogeneic BALB/c splenectomised recipients 
(Figure 4.21).The prolongation of survival of ephrin B2-/- grafts compared to the wild-type 
grafts in this experiment was less pronounced than in the previous experiment (section 
4.4). This may be due to the fact that in these experiments recipient mice received two 




Figure 4.21- Survival of double ephrin B2-/- skin grafts compared with double wild-type skin grafts 
in allogeneic BALB/c recipients. 
Either, two ephrin B2-/- or two wild-type skin grafts were transplanted onto splenectomised BALB/c 
recipients and survival monitored. Ephrin B2-/- grafts survived longer with an MST of 18 days 





Following this result, BALB/c recipients were transplanted with both a wild-type and an 
ephrin B2-/- graft simultaneously. When BALB/c recipients received one wild-type and 
one ephrin B2-/- graft simultaneously, there was still a survival advantage of ephrin B2-/- 
grafts compared with wild-type grafts. Ephrin B2-/- grafts survived longer (MST=19 days) 




Figure 4.22- Survival of double ephrin B2-/- skin grafts compared with double wild-type skin grafts 
on allogeneic BALB/c recipients. 
Splenectomised BALB/c mice were transplanted with one ephrin B2-/- and one wild-type graft, and 
survival was monitored. Ephrin B2-/- grafts survived longer with an MST of 19 days compared to 
wild-type grafts with an MST of 16 days. N=6 in each group. p=0.0076. 
 
 
Therefore, rejection of ephrin B2-/- grafts compared with wild-type grafts followed the 
same pattern in the case of co-transplantation onto the same recipient (Figure 4.22), as 
when two of the same type were transplanted onto one recipient (Figure 4.21). This data 
suggests that the beneficial effect on survival seen in ephrin B2-/- grafts is limited to the 
local environment of the graft, and that the presence of an ephrin B2-/- graft cannot 
prolong the survival of a wild-type graft on the same recipient. This provides 
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circumstantial evidence for a direct effect of ephrin B2 deficiency in LECs on graft 
survival, rather than what was originally hypothesised, i.e. a downstream effect on 




The results presented in this chapter further confirm the role of lymphatics in the immune 
response to a transplanted organ. Mice with a conditional lymphatic-specific knockout of 
ephrin B2, a molecule known to be essential for lymphatic function, were used as organ 
donors in allogeneic skin, heart and kidney transplantation models. There were no gross 
differences in the lymphatic networks within ephrin B2-/- grafts before transplantation, nor 
did they have reduced immunogenicity due to the knock-out. However, when 
transplanted into allogeneic recipients they survived significantly longer than their wild-
type counterparts. This effect was consistent across all organs studied; skin, heart and 
kidney. Trafficking of donor cells from the graft to the DLN in the immediate post-
transplantation period was assessed by PCR, and no difference was found between 
ephrin B2-/- and wild-type transplants, meaning that the observed effect on survival could 
not be attributed to diminished trafficking of DPL from ephrin B2-/- grafts. This was further 
confirmed by assessing survival of ephrin B2-/- skin grafts in the presence of a wild-type 
graft. If there was in fact diminished trafficking of DPL from ephrin B2-/- grafts, the 
improvement in survival would be reversed because trafficking of DPL from the co-
transplanted wild-type graft would overcome the defect. However, this wasn’t the case 
and ephrin B2-/- grafts maintained their survival advantage over wild-type grafts even in 
the presence of canonical trafficking from the wild-type graft.  
 
In conclusion, grafts with ephrin B2 deficiency in LECs reject at a significantly slower rate 
than wild-type grafts in allogeneic recipients; and this effect cannot be attributed to a 
defect in trafficking of DPL out of the graft or reduced immunogenicity of the graft. It is 
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therefore likely that the effect on survival is due to a direct effect of ephrin B2 deficiency, 




In order to build on evidence from chapter 3 that the lymphatic system plays a role in the 
immune response to a transplanted organ, particularly in the trafficking of cells between 
the graft and the DLN, a mouse with a lymphatic deficiency was used. Research in the 
field of lymphatic biology is limited by the availability of knock-out mice models. Most 
mice models with a defect in the lymphatic vasculature do not survive to adulthood, as 
the lymphatic system is vital for drainage of fluid from the peripheral organs and 
transportation of this fluid back into the blood circulation. Without functional lymphatics, 
fluid either builds up in the organs themselves or fluid draining from the periphery fails to 
drain into the thoracic duct and builds up in the chest cavity leading to the fatal condition 
chylothorax. The model available to our laboratory at the time was a conditional knockout 
of ephrin B2 in LECs. This removes the obstacle of lethality as the knockout can be 
induced in adulthood at the time of the experiment. It did however limit the use of the 
knockout to the donor in the transplantation models presented here, as this knockout is 
still lethal eventually and therefore was not suitable to induce in recipient mice which 
would need to remain alive for assessment of graft survival.  
 
The eph/ephrin signalling molecules are best known for their function in development, 
particularly for the role they play in neuronal guidance (reviewed in (239)); however, it is 
now clear that this pathway is active in many cell types in adult organisms and has been 
implicated in pathologies such as oncogenesis (240). The eph/ephrin pathway is used 
by cells for repulsion and adhesion during patterning processes and thus there is an 
interest in targeting this pathway for anti-cancer therapy to inhibit communication 
between tumour cells. This pathway is also recognised as highly important during 
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development of the blood and lymphatic vasculature, in particular the ephrin B2 ligand. 
Hence why it was chosen for study here. Although much of the research into the role of 
ephrin B2 in lymphatic function has been carried out in developmental models, where it 
is important for lymphatic valve formation in collecting vessels, it has also been shown 
to be crucial for VEGF-C-induced lymphangiogenesis. Ephrin B2 is critical for 
internalization of the VEGF-C receptor VEGFR3, and in its absence signalling 
downstream of VEGFR3 is halted, which in turn inhibits growth of new lymphatic vessels 
(117). Ephrin B2 blocking antibodies have been used successfully to block growth of new 
vessels in experimental tumour models (164). 
 
Taking this evidence from the literature for the role of ephrin B2 in lymphatic function and 
lymphangiogenesis, it was hypothesised that a lymphatic-specific deletion of ephrin B2 
in donor organs would impact graft survival. The results presented in this chapter confirm 
this hypothesis; ephrin B2-/- grafts survived significantly longer in allogeneic recipients 
than control grafts. Survival of all organs studied (skin, heart and kidney) was significantly 
prolonged when ephrin B2 was knocked out in LECs compared with controls. Removal 
of the spleen was essential for the prolongation of survival in heart and kidney but not 
skin allografts. This is likely to be because the spleen is not an important location for allo-
antigen recognition in skin transplantation, as skin grafts are not vascularised, making it 
more difficult for DPL to traffic via blood to the spleen of the recipients. Ephrin B2-/- kidney 
grafts in splenectomised recipients survived indefinitely, with good kidney function and 
histological features previously seen in tolerant grafts (186). This is probably due to the 
reduced immunogenicity of kidney grafts compared with skin and heart, rather than as a 
result of a stronger or different immunological effect of knocking out the ephrin B2 gene 
in the donor kidney.  
 
Prolonged survival of ephrin B2-/- grafts could not be attributed to a defect in DPL 
trafficking from the ephrin B2-/- grafts to the DLN in the immediate post-transplantation 
period, as there was no difference in the number of donor cells trafficking to recipient 
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DLN from ephrin B2-/- compared with wild-type grafts at 24 hours after transplantation. In 
addition, there were no microscopic differences in lymphatic structure and density 
between ephrin B2-/- and wild-type organs before transplantation. Furthermore, long-term 
surviving ephrin B2-/- kidney grafts had lymphatic vessels which could be observed after 
LYVE-1 staining at day 100, indicating that in this model lymphatic vessels are not 
completely ablated. Although it would be essential to confirm that these lymphatics are 
not of recipient origin which would indicate that they are a result of post-transplantation 
lymphangiogenesis rather than donor lymphatics unaffected by tamoxifen treatment. The 
proportions and absolute numbers of CD11c+ and CD11b+ cells within ephrin B2-/- hearts 
before transplantation was also unaffected. This suggests that lymph and cells are still 
able to leak from the severed graft lymphatics of ephrin B2-/- organs in the same manner 
as in the wild-type. Therefore, it is likely that knocking out ephrin B2 in LECs of the graft 
has a direct impact on the immune response following transplantation, rather than 
affecting downstream events such as trafficking of cells via lymphatics between the graft 
and DLN.  
 
As ephrin B2 signalling has also been implicated in immune regulation and activation, 
this may be a possible explanation for the prolonged survival of ephrin B2 knockout 
grafts. Ephrin B2 has been shown to be able to act as a co-stimulator of T cells (121), 
and as LECs have the ability to present antigen to T cells (241), deletion of ephrin B2 in 
this model and the subsequent effect on survival of allografts could be explained by this 
mechanism. 
 
Ephrin B2 has also been associated with endothelial transmigration of cells, particularly 
monocytes (242). Although no difference was found in the kinetics of DPL trafficking in 
the immediate post-transplantation period in the model presented here, it’s possible that 
by investigating in more detail different time points and phenotypes of trafficking cells, 





 Lastly, there is evidence that ephrin B2 can activate monocytes in disease settings such 
as atherosclerosis (119). Braun et al. showed that ephrin B2 is located on the luminal 
side of arteries and interacts with the ephB4 receptor on monocytes aiding their trans-
differentiation into inflammatory macrophages. This could explain the reduced 
immunogenicity of ephrin B2-/- grafts in the model presented here. 
 
Therefore, there are multiple possible mechanisms to explain the effect, on allograft 
survival, of lymphatic-specific deletion of ephrin B2 in the models presented in this 
chapter. By investigating in more detail the specific interactions between LECs in the 
graft and leukocytes trafficking between the graft and secondary lymphoid organs, a role 
for ephrin B2 in the allo-immune response could be uncovered, which would pave the 











Lymph nodes are highly organized structures that are essential for optimal encounters 
between APCs and T cells required to mount an effective immune response. In addition 
to cells of the immune system, lymph nodes possess an intricate network of stromal cells 
that act to guide leukocytes to different compartments, ensuring optimal interactions for 
an immune response. Lymph node stromal cells consist of: blood endothelial cells, which 
line the blood vessels within the lymph node including high endothelial venules; follicular 
dendritic cells, which reside in follicles and aid B cell survival; fibroblastic reticular cells 
(FRCs), which are present throughout the cortex and T cell areas and help in the support 
of HEVs and promotion of T-cell survival; and finally LECs, which line the afferent and 
effect lymphatic vessels, the medullary sinuses and the subcapsular sinuses, and guide 
leukocytes through the lymph node by secretion of CCL21. Although originally thought 
of as purely structural, these stromal cell types are now known to play active roles in the 
co-ordination of immune cell trafficking and survival (reviewed in (187)). 
 
LECs line lymphatic vessels within lymph nodes and in peripheral organs. The recent 
development of techniques to isolate this cell population from human and mouse tissue 
has led to a wealth of information regarding their role in the immune response (122). 
LECs are characterised by expression of podoplanin, an integral membrane 
glycoprotein, and CD31 (also known as platelet endothelial cell adhesion molecule 1), 
an endothelial cell marker. They constitutively secrete the chemokine CCL21 for 
homeostatic migration of APC from the periphery to the lymph nodes and movement of 
leukocytes within the lymph node (243). Upon inflammation they upregulate expression 
of CCL21 and other chemokines for active recruitment of leukocytes from tissue 
parenchyma (244). They also express danger sensing receptors such as TLRs (139). 
 
In addition to actively recruiting leukocytes to the lymphatic vessels and lymph nodes, 
LECs express a variety of molecules that have a direct impact on leukocyte function. 
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They upregulate ICAM-1, ICAM-2, VCAM-1 and CD62E in response to inflammation, 
which function to aid leukocyte adhesion and transmigration across the lymphatic 
endothelium, and thus entry to the lymph node. They are also known to express MHC 
class I and present antigen to CD8+ T cells. The function of antigen presentation by LECs 
is to induce tolerance of CD8+ T cells to self-antigen. Lymph node LEC express a range 
of peripheral tissue antigens, and present them to CD8+ T cells in the presence of high 
levels of PDL1, which engages PD1 on T cells and leads to their deletion (155, 196). 
LECs also express MHC class II and upregulate expression in response to inflammation. 
They lack the ability to load endogenous antigen onto MHC class II because they do not 
express H-2M, however they do acquire MHC class II-peptide complexes from dendritic 
cells (199). For some time the function of MHC II expression by LECs was unknown; 
however, it is now becoming clear that it plays a regulatory role. Work from the lab of 
Melody Swartz concluded that interactions between MHC class II-peptide-expressing 
LECs and CD4+ T cells led to deletion of the T cells by apoptosis; DC activation of CD4+ 
T cells was also inhibited when LECs were added to the culture (245). In addition to 
PDL1 and MHC class II, LECs express conventional co-stimulatory molecules such as 
CD80 and CD40, albeit at low levels (246). 
 
Taking this evidence from the literature it is clear that LECs within lymph nodes do not 
just provide conduits for trafficking immune cells; they can also directly impact the cells 
they come into contact with via a range of mechanisms that are dependent on the 
inflammatory milieu. This led to the hypothesis that LEC in lymph nodes draining a 
transplanted organ would undergo phenotypic changes in response to transplantation. 
In order to test this hypothesis, LECs were isolated from DLN of mice that had received 





5.2 Assessing changes in draining lymph node LEC phenotype 
following heart transplantation 
In order to investigate phenotypic changes of DLN LEC in response to transplantation, 
heterotopic heart transplantation was performed between donor BALB/c and recipient 
C57BL/6 mice, and DLN were harvested at day three (Figure 5.1). This time point was 
chosen after examination of the literature, based on studies of LEC responses to 
inflammatory stimuli (246). 
 
 
Figure 5.1- Experimental design for assessment of phenotypic changes in lymph node LECs after 
transplantation.  
Fully allogeneic BALB/c donor heart grafts were transplanted into C57BL/6 recipients. Three days 
after transplantation, draining lymph nodes were harvested for analysis. 
 
 
Mediastinal lymph nodes were harvested from heart transplant recipients at day three, 
digested according to a published protocol (218), and the LECs analysed by flow 
cytometry. In order to gate the LECs from the total lymph node sample, debris from the 
digestion process was first gated out on the forward vs. side scatter plot, and single cells 
gated. Subsequently, live CD45- cells were gated on in order to analyse the stromal cell 
compartment and not the leukocytes. Lastly, a scatter plot of podoplanin vs. CD31 was 
created to identify the three stromal cell compartments: blood endothelial cells (CD31+ 
podoplanin-), fibroblastic reticular cells (CD31- podoplanin+), double negative cells 





Figure 5.2- Gating strategy for lymph node LECs. 
Draining lymph nodes were harvested from heart transplant recipients at day 3, digested and the 
cells isolated. Cells were gated according to (a) scatter properties, (b) single cells, and (c) dead 
cells stain exclusion and CD45 negativity. These cells were then analysed for expression of 
podoplanin and CD31 which results in identification of four distinct populations (d) double negative 
cells (Q4), blood endothelial cells (Q3), fibroblastic reticular cells (Q1), and LECs (Q2).  
 
 
The LEC population from each lymph node sample was then analysed for expression of 
PDL1 and MHC class II, to find out if there was upregulation of these molecules in 
response to transplantation. In order to quantify any phenotypic changes in LECs from 
DLN of heart transplant recipients, LEC expression of the markers mentioned above was 
compared to naïve controls, i.e. lymph node LECs from mediastinal lymph nodes of mice 
that had not received a transplant. In addition to this, syngeneic transplantation was also 
performed between C57BL/6 donors and recipients in order to test whether any 
phenotypic changes observed in LECs were due to the inflammation caused by 





There was no significant difference in expression of PDL1 or MHC class II between naïve 
lymph node LECs and LECs from DLN of transplant recipients; either syngeneic (PDL1, 





Figure 5.3- Phenotype of DLN LECs following transplantation. 
Draining lymph nodes were harvested from heart transplant recipients at day 3, digested and the 
cells isolated and analysed by flow cytometry. LECs were gated according to Figure 5.2 and the 
expression of (a and b) PDL1 and (c and d) MHC class II quantified. There was no difference in 
expression of PDL1 on LECs after syngeneic (p=0.8168) or allogeneic (p=0.6754), or MHC class 
II after syngeneic (p=0.4279) or allogeneic (p=0.5304). Each data point represents one mouse. 








5.3 Assessing DLN lymphangiogenesis following transplantation 
Lymph nodes draining areas where inflammation is present undergo lymphangiogenesis, 
whereby the lymphatic vessels expand to allow increased drainage from the inflamed 
area and to improve the chances of an encounter between APCs and T cells. This 
process is particularly prevalent in cancer, where it has been linked to progression of the 
disease via metastasis (247). Therefore, it was hypothesised that lymph node lymphatic 
vessels in draining lymph nodes would expand in response to transplantation, and that 
this results in an increase in the size of the LEC population recovered from DLN of heart 
transplant recipients when compared to lymph nodes from naïve mice. The proportion of 
LECs DLN samples was quantified using the samples from the experiment described 
above (Figure 5.2) There was no significant difference in the proportion of the total that 
were LECs within the DLN of transplant recipients compared with naïve controls 
(0.006±0.001% (syngeneic) and 0.004±0.0009% (allogeneic) vs. 0.007±0.002%, 




Figure 5.4- Quantification of DLN LECs after transplantation (proportion).  
Draining lymph nodes were harvested from heart transplant recipients at day 3, digested and the 
cells isolated and analysed by flow cytometry. LECs were gated according to Figure 5.2 and the 
size of the LEC population quantified as a proportion of the total. There was no difference in the 
size of the DLN LEC population after syngeneic (p=0.6734) or allogeneic (p=0.2869) when 
compared to the LEC population within naïve mediastinal lymph nodes. Each data point 





This result was confirmed by calculating the absolute number of LECs in each lymph 
node sample using the total number of cells recovered following the digestion protocol. 
Again, there was no significant difference in the total number of lymph node LEC 
between transplant recipients (both syngeneic and allogeneic) and naïve controls 
(190±68 (syngeneic) and 134±32 (allogeneic) vs. 162±58 cells, p=0.7652 and 0.6881 




Figure 5.5- Quantification of DLN LECs after transplantation (absolute number).  
Draining lymph nodes were harvested from heart transplant recipients at day 3, digested and the 
cells isolated and analysed by flow cytometry. LECs were gated according to Figure 5.2 and the 
size of the LEC population quantified in terms of the number of cells in the sample. There was no 
difference in the size of the DLN LEC population after syngeneic (p=0.7652) or allogeneic 
(p=0.6881) when compared to the LEC population within naïve mediastinal lymph nodes. Each 




Taken together, these results show that following heterotopic heart transplantation there 
is no change in expression of PDL1 and MHC class II on DLN LECs three days after 
syngeneic or allogeneic cardiac transplantation. In addition, there is no expansion of the 
lymphatic network within these DLN as demonstrated by calculating the proportion and 
absolute numbers of LECs in each sample. In conclusion, there is no measurable 
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Lymph nodes draining areas of inflammation and tumours are known to undergo 
lymphangiogenesis. This process enhances APC migration from the inflamed region 
(248), and thus amplifies the immune response. In cancer, lymph node 
lymphangiogenesis allows for successful metastasis from the peripheral tumour to the 
local lymph nodes, and therefore disease progression. It is as yet unknown whether or 
not lymph node lymphangiogenesis occurs following solid organ transplantation.  
 
Lymph node LEC are important mediators of the immune system as they can present 
self-antigen in the context of MHC class I for induction of CD8+ T cell tolerance. This 
occurs via a PDL1-dependent mechanism, in spite of the fact that LECs also express 
conventional co-stimulatory molecules. The function of MHC class II expression by LECs 
is less well understood, although emerging evidence points to a regulatory role. 
 
Our group has identified the DLN in heterotopic heart transplantation in the mouse as 
the mediastinal lymph nodes. As these lymph nodes are one of the sites of induction of 
the T cell response to the allograft, it is expected that changes to the phenotype of LECs 
could affect the immune response. The experiment presented in this chapter aimed to 
assess the response of DLN LECs to transplantation, both in terms of 
lymphangiogenesis and phenotypic changes in the cells themselves. 
 
Heterotopic heart transplants were performed between syngeneic and allogeneic strain 
combinations and the DLN were harvested at day three. LECs were obtained by careful 
digestion of the tissue and analysed by flow cytometry. The proportion and total numbers 
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of LECs in the samples were calculated, and no significant differences were found 
between transplant recipient lymph nodes and naïve controls. In addition, there was no 
difference in expression of PDL1 and MHC class II between transplant recipient lymph 
nodes and naïve controls. 
 
Lymphatic remodelling and growth of new lymphatic vessels by lymphangiogenesis at 
tumour sites and in lymph nodes draining tumours is a well-studied process that plays a 
role in the progression of the disease (141). It is also known that lymphatic remodelling 
occurs in transplanted organs, although the outcome of the process in this case is less 
clear. As presented in chapter 1 there is evidence for both a positive and negative effect 
of lymphangiogenesis on graft outcome, with convincing data on both sides of the 
argument. Increased lymphatic vessel density within the graft could enhance DC 
migration to the DLN for activation of antigen-specific T cells, or could increase drainage 
of graft destructive T cells away from the graft; both cell types are known to traffic via the 
lymphatics. Although there have been studies on graft lymphangiogenesis, there is no 
evidence from the literature to show that lymphangiogenesis occurs in lymph nodes 
draining transplanted organs (172). The experiment presented here aimed to assess 
this. Following heterotopic heart transplantation, there was no expansion of DLN 
lymphatics by day 3 after transplantation. The DLN response to transplantation was 
measured by flow cytometry, which limits data to number of certain cell types based on 
expression of surface markers. Immunohistochemistry could be used in conjunction with 
flow cytometry to show the location of lymphatic vessels and whether or not there were 
any structural changes. In addition, for this experiment one time point was chosen. This 
was based on studies of lymph node phenotypic changes from the literature available at 
the time. Many of these studies look at LECs in culture, which are likely to respond 
differently to cells in a lymph node of a live mouse. Therefore, in the fullness of time a 
variety of time points following transplantation would be chosen and the phenotypic 
changes of LECs studied to see if these cell do respond to transplantation.  It would also 
be beneficial to study DLN LECs from transplant recipients in vitro to test whether or not 
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they can prime allo-reactive T cells. An experiment using human primary LEC cultures 
has shown that LECs disrupt allogenic DC/T cell interactions via production of 
indoleamine 2,3 dioxygenase (246). Studying co-cultures of DLN LECs from transplant 
recipients with allogeneic DCs and T cells in the transplantation model presented here 
would help to provide evidence for a role of lymphatics outside of providing a passive 










6.1 Using anti-ICAM-1 antibody therapy to block post-transplantation 
lymphatic trafficking of DPL 
6.1.1 Summary of findings 
Trafficking of cells from the graft to SLO is essential for the initiation and maintenance of 
an immune response against the graft. The seminal paper by Lakkis et al. first 
demonstrated the importance of the SLO in transplantation. The direct pathway of allo-
recognition is active in the immediate post-transplantation period and relies on efficient 
trafficking of DPL out of the graft towards the DLN and spleen. Although the involvement 
of the blood route to the spleen has been well studied, the lymphatic route out of the graft 
has received little attention.  
 
Presented in chapter 3 are results from experiments that aimed to pharmacologically 
block the lymphatic route of DPL trafficking from the graft to the DLN in a mouse kidney 
transplantation model. Recipient female mice were treated with anti-ICAM-1 antibody or 
vehicle control before receiving a male kidney graft. They also received a splenectomy 
so that the lymphatic route of DPL trafficking could be studied in isolation.  
 
Firstly, the kinetics of DPL trafficking to recipient DLN was assessed using a donor-
specific real-time PCR assay. There was a reduction in the amount of donor DNA in 
recipient DLN after anti-ICAM-1 antibody treatment compared with vehicle control, 
suggesting that treatment with anti-ICAM-1 before transplantation reduced trafficking of 
DPL out of the graft towards the DLN in the immediate post-transplantation period. 
 
Next, the effect of anti-ICAM-1 antibody therapy on the survival of allografts was 
assessed. Treatment with anti-ICAM-1 before transplantation in conjunction with a 
splenectomy did lead to prolonged, and in some cases indefinite, survival of the allograft. 
Long-term surviving anti-ICAM-1 antibody-treated grafts also benefited from normal graft 
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function. This indicated that the lymphatic route of trafficking of DPL out of the graft post-
transplantation plays an important role in the rejection process. 
 
In order to see if the prolonged survival observed in anti-ICAM-1 antibody-treated 
recipients was due to a reduction in T cells infiltrating the graft, the T cell infiltrate of 
recipients was assessed at day five after transplantation. Grafts from anti-ICAM-1 
antibody-treated grafts had a similar degree of T cell infiltration, including Foxp3+ cells, 
than those from vehicle control treated-recipients.  
 
 
6.1.2 Implications and limitations 
The results from chapter 3 highlight the importance of post-transplantation trafficking of 
DPL out of the graft and towards the recipient DLN. When this pathway was blocked with 
anti-ICAM-1 antibody, there was a reduction in the proportion of donor DNA in recipient 
draining lymph nodes, most likely as a result of fewer DPL leaving the graft via the 
lymphatic route. This translated into improved survival of kidney allografts in anti-ICAM-
1 antibody-treated, splenectomised recipients. These results demonstrate the potential 
for therapeutics targeting lymphatic trafficking in transplantation patients, as an adjunct 
to traditional immunosuppressive drugs.  
 
It is important to bear in mind that the model used in these experiments is relatively ‘soft’ 
in terms of immunogenicity. Kidney transplants between BALB/c donor and C57BL/6 
recipient mice can undergo spontaneous acceptance in a small number of recipients, 
albeit with poor graft function (186). Therefore, a vehicle control-treated and non-
splenectomised control group was included. Indeed, in this group one out of four kidney 
allografts survived until day 81; however, the BUN increased over the course of the 
experiment indicating deteriorating kidney function. Although the case of this long-term 
surviving recipient wouldn’t be referred to as spontaneous acceptance, it is clear from 
previous studies in our laboratory (186), and from the literature (249), that spontaneous 
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acceptance of kidney allografts in mice is a recognized phenomenon, and therefore any 
results pointing to prolonged survival in following anti-ICAM-1 antibody therapy should 
be interpreted with caution; although the much higher than control permanent 
acceptance rate and superior graft function is very strong evidence for the beneficial 
effect of anti-ICAM-1 treatment. In addition, there is a degree of heterogeneity in kidney 
transplant outcome within groups which is likely due to variations which occur in the 
transplant procedure, such as; differences in anatomy, differences in reaction to 
anaesthetics and analgesics, and differences in cold and warm ischemia times. All of 
these factors have the potential to affect DPL trafficking out of the graft. It is likely that 
this beneficial effect is only modest and is unlikely to replace the need for long term 
immunosuppressive treatment in the clinic, but may be able to reduce the total amount 
of immunosuppression required and or to reduce the frequency and severity of acute 
rejection. 
 
In these experiments the anti-ICAM-1 antibody was administered IV and was therefore 
likely to have effects additional to blocking lymphatic trafficking of DPL. ICAM-1 is widely 
expressed on different cell types throughout the body, and functions in many biological 
processes. The half-life of the anti-ICAM-1 antibody used in these experiments is 
unknown and it would be important to determine this is order to fully rule out any effects 
of the antibody on rejection processes which occur after trafficking of DPL out of the 
graft. Particularly, the role of integrins such as LFA-1 (the receptor for ICAM-1) has been 
well studied in the context of T-cell migration, activation and memory function. Naïve T 
cells migrate from the blood to SLO in an integrin-dependent manner. In addition, 
interactions between T cells and DCs, necessary for T-cell differentiation, are dependent 
on the ICAM-1/LFA-1 axis. And finally migration of antigen-specific activated T cells into 
inflamed or infected tissue is integrin-dependent (reviewed in (250)). Activation and 
differentiation of antigen-specific T cells in SLO, and homing of these cells to the graft, 
are critical steps in the initiation of rejection. Therefore, by blocking ICAM-1 
pharmacologically in these experiments, there may have been an effect on T-cell 
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activation and migration to the graft. The T-cell response was analysed at day five 
following transplantation, and infiltration of T cells into the anti-ICAM-1 antibody-treated 
grafts was observed. One dose of antibody was administered before transplantation, and 
is likely cleared from the system so that events following DPL migration out of the graft, 
such as T-cell activation and migration, are unaffected. However, this would have to be 
evaluated in this model to rule out effects of anti-ICAM-1 antibody on the T-cell response 
to the allograft. The fact that there were T cells infiltrating donor kidneys in anti-ICAM-1 
antibody-treated recipients supports the notion that the dosing schedule used here has 
not hindered T cell infiltration and that the beneficial effect was more likely to be via its 
effect on DPL trafficking. Unfortunately, due to time constraints as a result of the 
technical challenges involved in mouse kidney transplantation, for the experiment 
presented in section 3.4 the numbers of mice would have to be increased in order to 
accept the null hypothesis that there are no differences between the two groups. 
 
Therapies targeting both ICAM-1 (Enlimomab (251)) and LFA-1 (Efalizumab (252)) have 
been trialled in renal transplant patients with some success. The rationale for using these 
antibodies was mainly based on their influence on T-cell infiltration of the graft rather 
than prevention of DPL trafficking out, as was the case for the study presented here. 
Efalizumab was trialled for safety in combination with conventional immunosuppression 
(ciclosporin and mycophenolate mofetil), and the results showed no increase in the 
incidence of acute rejection; however, 8% of patients receiving a high dose of Efalizumab 
in conjunction with immunosuppression developed post-transplant lymphoproliferative 
disease. Enlimomab has shown efficacy in renal transplant patients; however, a 
subsequent trial raised concerns over the possible activation of neutrophils, leading to 
fever and leukopenia (253).  
 
As ICAM-1 is an abundantly expressed molecule throughout the body and therefore 
pharmacological blocking is not specific to the lymphatic endothelium, more pronounced 
effects on post-transplant trafficking of DPL out of the graft may be seen with a more 
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lymphatic-specific target. LYVE-1, the lymphatic vessel hyaluronan receptor, is primarily 
expressed on lymphatic endothelium, and is an attractive target for blocking lymphatic 
trafficking of leukocytes. Initial studies on a LYVE-1 global knock-out mouse showed no 
defects in lymphatic development and function, including trafficking of DCs between the 
skin and draining lymph nodes (254). However, more evidence has emerged showing 
that expression of hyaluronan on the surface of monocyte-derived macrophages leads 
to engagement with LYVE-1 on lymphatic endothelium and subsequent transmigration 
(255). In addition, group A streptococcus, which has a hyaluronan capsule, rapidly 
disseminates through the body via the lymphatic system, and its entry into lymphatics 
has been shown to be LYVE-1-dependent (256). Taking this evidence from the literature, 
LYVE-1 would be a suitable target for blocking lymphatic trafficking of DPL post-
transplantation, and an anti-LYVE-1 antibody could be used as an alternative to the anti-
ICAM-1 antibody, to provide more specific targeting of lymphatic trafficking of DPL after 
transplantation. 
 
The complex mechanisms involved in lymphatic trafficking of leukocytes are only now 
beginning to be elucidated. It is likely to be the case that many molecules and pathways 
are involved, and that different mechanisms will be used by diverse cell types depending 
on the microenvironment and inflammatory signals. Therefore, it will be important to 
study in more detail the mechanism of DPL migration via lymphatics in transplantation 
models, as this route provides a potential avenue for adjunctive immunosuppressive 






6.2 Effects of disruption to donor lymphatics on the allo-response 
6.2.1 Summary of findings 
The lymphatic vessels within the graft are the point of entry of DPL, trafficking via this 
route, into the recipient. The role of graft lymphatics in this context has not previously 
been studied in transplantation models. Ephrin B2-/- mice were used as donors to assess 
the contribution of donor lymphatics to the allo-response. 
 
Firstly, the effect of ephrin B2 deficiency on the cellular composition of donor organs was 
assessed. There were no differences in the proportions and numbers of CD11c+ and 
CD11b+ from ephrin B2-/- hearts compared with wild-type controls. CD11c+ and CD11b+ 
leukocytes from ephrin B2-/- and wild-type hearts also displayed no differences in 
expression of molecules involved in antigen presentation: MHC class II and CD80. 
Therefore, ephrin B2 deficiency had not effected the density or phenotype of APCs within 
the donor organ before transplantation. 
 
The gross structure of the lymphatic vessels within donor organs was also assessed, 
and there were no differences in lymphatic density and size of vessels within skin, heart 
and kidney tissue, between ephrin B2-/- and wild-type animals. 
 
All types of ephrin B2-/- organs assessed (skin, heart and kidney) survived significantly 
longer in fully allogeneic recipients compared with control organs. This demonstrated 
that deficiency of ephrin B2 conferred a survival advantage on donor organs. In order to 
assess whether or not this survival advantage was due to reduced trafficking of DPL out 
of ephrin B2-/- grafts as a result of dysfunctional lymphatics, as originally hypothesised, 
DPL within recipient DLN were quantified 24 hours after transplantation. There were no 
differences in proportion of donor DNA and number of donor cells within recipient 
draining lymph nodes at 24 hours after transplantation between recipients of ephrin B2-




In order to assess whether or not the survival advantage of ephrin B2-/- grafts was a 
dominant effect, a double skin transplantation model was evaluated, whereby recipient 
mice received two skin grafts simultaneously, one from an ephrin B2-/- donor and one 
from a wild-type donor. Survival of these mixed double skin transplants in allogeneic 
recipients was compared with survival of two grafts of the same type. The mixed double 
skin transplants behaved in the same way as the same type skin grafts, in that ephrin 
B2-/- grafts survived longer than wild-type grafts, suggesting that the graft protective 
effect of knocking out the ephrin B2 gene is exerted within the donor graft itself.  
 
In conclusion, ephrin B2 deficiency in LECs provided a protective effect to transplanted 
organs, with all graft types surviving significantly longer in allogeneic recipients 
compared with control grafts. However, this effect is likely not due to a defect in lymphatic 
trafficking of DPL out of the graft in the immediate post-transplantation period, and is 
more likely to be due to a direct effect of ephrin B2 deficiency in the graft. 
 
 
6.2.2 Implications and limitations 
The results from chapter 4 provide evidence that ephrin B2 deficiency in LECs of grafts 
leads to significantly prolonged survival following allogeneic transplantation. Therefore, 
therapeutic targeting of graft lymphatics, especially via ephrin B2, in transplant patients 
could be used in addition to traditional immunosuppression to prolong graft survival. 
Although the original hypothesis for this experiment was that ephrin B2 deficiency would 
affect trafficking of DPL out of the graft towards the DLN via the lymphatics, this was not 
the case, and it is more likely that ephrin B2 deficiency provided a local protective effect. 
Due to technical difficulties in analysing small populations of DPL that have trafficked 
into the DLN, it was not possible to perform detailed phenotypic analyses to determine 
whether differences in the sub-populations of DPL trafficking out of ephrin B2-/- grafts 
could be responsible for the graft prolongation effect. It is possible that cells trafficking 
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via defective lymphatics (i.e. ephrin B2-/-) have an altered phenotype, providing an 
alternative explanation for the prolongation of survival of these grafts. 
 
Antibodies targeting ephrin B2 are available and have been used to halt 
lymphangiogenesis in tumour models, with promising results in terms of reducing tumour 
size (164). In addition, there are clinical trials ongoing with drugs targeting a variety of 
eph/ephrin axes for anti-cancer and neurodegenerative therapies (257). The fact that 
therapeutic targeting of ephrins has proven to be efficacious and safe for patients, and 
there are agents available, suggests it could be a promising strategy for anti-rejection 
therapy in transplant recipients, based on the findings from chapter 4. 
 
Studying the lymphatic system in transplantation models is limited by the availability of 
knock-out mice with a non-lethal defect in lymphatic function. Functional lymphatics are 
essential for survival, therefore many of the knockout mice available do not survive to 
adulthood. For these experiments a conditional knock-out was used so that adult mice 
were available; however, ephrin B2 deficiency in LECs is eventually lethal so these mice 
could not be used as recipients in the models presented here. This fact limited the use 
of ephrin B2-/- mice to the donor strain in transplantation models; and they were used at 
a time point before showing any outward signs of lymphatic dysfunction. Since the 
experiments for chapter 4 were completed, a variety of novel mouse models for lymphatic 
dysfunction have been generated. Sugaya et al. have developed a mouse model of 
lymphatic dysfunction, in which, animals transgenically express the Kaposi’s sarcoma 
herpes virus associated latency gene k-cyclin (k-CYC) under the control of the VEGFR3 
promoter. These mice display augmented primary tumour growth associated with a 
reduction of pro-inflammatory cytokine production in DLN, and decreased cytotoxic 
activity of tumour specific CD8+ T cells. However these mice do succumb to chylothorax 
eventually so their use is limited (258). Gardenier et al. have generated a mouse with a 
diphtheria toxin receptor (DTR) specifically expressed on LEC. Their model is also 
temporally and spatially conditional as it contains a cre recombinase gene linked to the 
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VEGFR3 promoter. After administration of tamoxifen, to induce DTR expression, and 
then diphtheria toxin specifically into the hind limb to ablate lymphatics in this region, the 
mice developed lymphedema identical to that seen in patients. They also defined a role 
for M2 macrophages in lymphatic regeneration following edema (259). This model would 
be useful to study the contribution of lymphatics to transplantation as lymphatics could 
be specifically ablated in the donor organ before transplantation, or systemically in the 
recipient. This would allow the contribution of both donor and recipient lymphatics to be 
assessed in parallel.  
 
Although ephrin B2 deficiency had a significant impact on graft survival in the 
transplantation models presented here, this could not be attributed to a reduction in 
trafficking of DPL out of the graft via the lymphatics, or reduced antigen presenting 
capacity of the DPL. Unfortunately, due to time constraints as a result of the technical 
challenges involved in isolating cells from mouse tissue, and the unforeseen 
heterogeneity in proportions of heart antigen presenting cells between individual mice, 
the experiment presented in section 4.5 is not sufficiently powered to draw the conclusion 
that there are no differences in antigen presenting cell numbers within wild-type hearts 
compared with ephrin B2-/- hearts. Numbers of mice would have to be increased in order 
to accept the null hypothesis that there are no differences between the two groups.   
Therefore, a mechanism for the effect on graft survival is yet to be elucidated. It is likely 
that prolongation of survival of ephrin B2-/- grafts is due to a direct effect of ephrin B2 
deficiency in LEC of the graft rather than a downstream effect on lymphatic trafficking. In 
order to investigate this further it would be beneficial to isolate LECs from ephrin B2-/- 
mice and investigate whether or not they have reduced capacity for interactions with 






6.3 Draining lymph node LEC response to transplantation 
6.3.1 Summary of findings 
Lymph node stromal cells are becoming increasingly recognised as regulators of the 
immune system. LECs and fibroblastic reticular cells, in addition to providing specialised 
conduit systems for trafficking immune cells within the lymph node, play a role in the 
maintenance of peripheral tolerance. Studies have shown that MHC class II expression 
by LECs may have a regulatory effect on CD4+ T cells, halting their proliferation (199). 
 
Lymph node expansion in response to inflammation is a well observed and characterized 
phenomenon. Expansion of lymphatic networks in DLN increases lymph flow from the 
affected area and increases the chance of antigen encounter by T cells, leading to a 
more effective immune response. Lymphangiogenesis in grafts is well described in 
kidney transplantation, although the contribution of this process to the immune response 
remains unclear. 
 
Lymph node LECs were isolated from the mediastinal lymph nodes of heart transplant 
recipients three days after transplantation, and analysed by flow cytometry. Firstly, the 
expression profile of a range of co-stimulatory and co-inhibitory molecules (PDL1, MHC 
II, CD80 and CD40) was assessed. DLN LECs from transplant recipients did not 
upregulate expression of any of the molecules that were evaluated. In addition, lymph 
node lymphangiogenesis was evaluated by quantifying the proportion and numbers of 
LECs within DLN from transplant recipients. There was no significant difference in 
proportion or absolute number of LECs between transplant recipients (either syngeneic 
or allogeneic) and naïve lymph nodes. 
 
In the fullness of time, a range of different time points after transplantation could be 
studied to see if lymph node lymphatics respond to transplantation either in the 




6.3.2 Implications and limitations 
Results from chapter 5 investigating the response of DLN lymphatics to transplantation 
did not find any phenotypic or structural changes following transplantation. These results 
should be interpreted with caution because only one time point after transplantation was 
assessed. Day three after transplantation was chosen as the time point as studies by 
others on the effects of inflammation on LEC phenotype had used this time point (196, 
201). However, these were studies on in vitro cultured LEC, and the inflammatory 
stimulus was directly applied to the cells in culture. The experiment presented here used 
primary LECs isolated from lymph nodes of mice that had received a heart transplant. It 
is currently unknown when exactly the inflammatory cytokines from a rejecting graft 
reach the DLN, although as DPL are present and detectable by 24 hours, it is likely that 
inflammatory cytokines arrive at the draining lymph nodes via the lymph at the same time 
or earlier. However, unlike in the case of DPL that are in a limited supply within the graft, 
inflammatory cytokines are constantly present within rejecting grafts and therefore the 
DLN will receive a constant supply of cytokines from the graft. This means that DLN LEC 
phenotype could vary throughout the lifetime of the graft, rather than just responding to 
inflammatory cytokines delivered to the DLN in the initial post-transplantation period. A 
range of time points would need to be studied to fully understand the response of DLN 
LECs to transplantation. It would also be interesting to measure the cytokine levels within 
the DLN at different time points to see if this correlates with LEC phenotype, and 
determine which cytokines are responsible for the changes observed. 
 
In terms of lymph node lymphangiogenesis in response to transplantation, this has yet 
to be studied by others. Therefore, it was difficult to determine which time point after 
transplantation to study. A study assessing the contribution of immune complexes to 
autoimmune disease progression looked at the DLN lymphatic response three days 
following immunization (260), and found differences in lymphatic density between control 
and experimental mice. As with LEC phenotype, lymphangiogenesis of draining lymph 
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node lymphatics following transplantation is likely to be a dynamic process with many 
factors involved at different time points. A comprehensive study of DLN lymphatics 
looking at LEC phenotype, cytokine composition of lymph nodes and molecules involved 





6.4 Concluding remarks 
A wealth of research in the past decade has led to the realisation that the lymphatic 
system plays a crucial role in immunity. Originally thought to simply provide a passive 
conduit system for removal of extra-cellular fluid and cells from tissue for return to the 
blood, the lymphatic system is now known to provide regulation of the immune response 
by: direct presentation of self-antigen by lymph node stromal cells to T cells, and 
orchestrated secretion of chemokines to guide immune cells out of tissue, and into and 
out of lymph nodes, in order to deliver a targeted adaptive immune response. This highly 
flexible system responds to disease caused by inflammation with the growth of new 
vessels within affected tissue and DLN exacerbating disease, and aids the spread of 
tumours by metastatic growth.  
 
Despite the vast knowledge of the role that the lymphatic system plays in the immune 
response to pathogens and the progression of cancer, there is limited information 
available in the literature about the function of the lymphatic system in transplantation. 
Transplantation provides a unique model for lymphatic research because there are donor 
and recipient lymphatics to consider, with the former expressing foreign antigens. 
Furthermore, the donor lymphatics are not directly connected to the recipient lymphatics 
during the initial post-transplantation period. Studies in this area have provided 
conflicting results. Some researchers have concluded that the lymphatic system, 
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particularly the lymphangiogenic response in graft tissue, has a negative impact on graft 
outcome, whereas others have provided evidence to the contrary.  
 
Transplantation saves the lives of patients living with end-stage organ failure. However, 
in order to protect grafts from the patient’s own immune system, immunosuppressive 
drugs have to be administered. These drugs have unwanted side effects due to their lack 
of specificity, and often diminish the life expectancy of the patient. Targeted therapy for 
transplant patients is needed, and therefore better understanding of the allo-immune 
response is required. 
 
This thesis aimed to investigate some of the roles of the lymphatic system in the immune 
response following transplantation. Mouse models of organ transplantation were used 
as they closely resemble the clinical situation and enable manipulation of the lymphatic 
system to decipher how this system functions during the allo-response. Some promising 
results have been presented here, with pharmacological blocking or genetic deletion of 
key molecules involved in lymphatic function leading to prolongation of graft survival. The 
results presented here have failed to support the original hypothesis that interfering with 
lymphatic function, either in the graft or the recipient, would reduce trafficking of DPL out 
of the graft towards the DLN and that in turn this would lead to sub-optimal priming of 
allo-specific T cells. As genetic modification of animals causing universal deletion of 
lymphatic vessels is embryonically lethal, it is not possible to use such models to study 
the effect of the absence of donor or recipient lymphatics in organ transplantation. Here 
a donor mouse with a conditional knockout of ephrin B2, which is crucial for lymphatic 
valve formation and function, was used as an alternative. However, in this model DPL 
trafficking was not affected as originally predicted. Therefore, the original hypothesis that 
interfering with lymphatic flow from the donor graft would prolong survival can neither be 
proved nor disproved with this model. Nonetheless, this model has provided evidence 
that suggests that dysfunctional graft lymphatics provide a local protective effect against 
rejection. Despite these interesting findings, more in depth analysis is needed to fully 
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elucidate the mechanisms of the prolonged survival seen in both models; the anti-ICAM-
1 antibody model and the ephrin B2-/- model. In addition, the results on lymph node LEC 
phenotypic and structural changes following transplantation were inconclusive and more 
time points need to be analysed. 
 
In conclusion, the lymphatic system of both the donor and recipient contribute to the 
immune response following transplantation, in ways beyond providing a conduit for 
trafficking immune cells. Lymphatic-specific therapies have the potential for use as 
adjunctive immunosuppression in transplant recipients. However, more research is 
needed to reveal in detail the dynamic roles of the lymphatic system in the immune 
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